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Abstract
Ebola’s severe pathogenesis can be attributed to its suppression of the Type I
interferon (IFN) response, suggesting this pathway plays a role in restricting viral
replication. One IFN-induced protein, HERC5, warrants further investigation as it
inhibits the replication of evolutionarily diverse viruses. We showed that HERC5
drastically reduces the expression of structural protein VP40 at the protein and mRNA
level. Mutagenesis of HERC5 demonstrated that the RCC-1-like domain is necessary and
sufficient for restriction. This domain is also responsible for HERC5’s interaction with
ZAP, a protein required for VP40 mRNA degradation. Finally, we showed that Ebola GP
antagonizes HERC5 activity. Overall, we have identified a novel antiviral mechanism
targeting Ebola RNA. Moreover, depletion of viral RNA via the RCC-1 like domain
identifies a previously unknown function for HERC5. Moving forward, this information
is crucial in building a solid foundation of knowledge regarding EBOV’s interaction with
the IFN response during infection.

Keywords
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CHAPTER 1: INTRODUCTION
1.1

Ebola virus disease
The latest Ebola outbreak in West Africa in 2014 recorded a staggering 28, 616

cases and 11, 325 deaths, demonstrating the severe and often lethal nature of Ebola virus
infection1. Ebola virus is a member of the Filoviridae family of negative sense RNA
viruses, with a filamentous morphology2. Though its natural reservoir is believed to be in
fruit bats, it is transmitted between humans through bodily fluid3. Once in the body, Ebola
virus first infects macrophages and dendritic cells and is accompanied by flu-like
symptoms after 8-12 days3,4. The migratory properties of macrophages and dendritic cells
allows for the spread of virus to fibroblasts, epithelial cells, hepatocytes and adrenal
cortical cells5. Ebola virus rapidly replicates within these cells, causing apoptosis and the
release of viral particles3,4. Circulation of extracellular particles leads to viral replication
within lymph nodes, and eventual ablation of this crucial defense line5. The body’s immune
defense is further deteriorated by infection and apoptosis of dendritic cells and suppression
of a key component of the innate immune defense, the Type I interferon (IFN) response6.
Extensive cell death and tissue necrosis ensues, inducing the release of massive amounts
of pro-inflammatory cytokines and a systemic inflammatory syndrome5.
The presence of pro-inflammatory cytokines and infection of endothelial cells are
responsible for vasodilation of blood vessels, downregulation of cell adhesion proteins,
pooling blood into various areas/tissues, and subsequent multi-organ failure known as
septic shock5,7. These cytokines are also responsible for inappropriate activation of
coagulation cascades which deplete circulatory platelets and cause an inability of blood to
clot5,7. The body is thus prone to excessive bleeding and hemorrhages, which characterizes
the quintessential hemorrhagic properties of the infection. An overall failure to clear this
infection typically results in death within 6-9 days after the onset of symptoms—making
Ebola virus one of the most virulent pathogens to infect humans7.
There are five species within the Ebola virus genus: Zaire ebolavirus (EBOV),
Sudan ebolavirus (SUDV), Bundibugyo ebolavirus (BDBV), Tai Forest ebolavirus
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(TAFV) and Reston ebolavirus (RESTV)8. Unlike TAFV, which has only been found to be
responsible for single, non-fatal infections of ebolavirus, SUDV, BDBV, RESTV and
EBOV have been responsible for past outbreaks of human infection8. Most notably, EBOV
is responsible for the 2014 outbreak in West Africa1. This outbreak not only shed light onto
the severe manifestations of the disease, but also emphasized the knowledge gap regarding
EBOV infection. The ability of EBOV to trigger the host immune response and cause
severe disease, without triggering an effective antiviral response, demands critical analysis
of the virus-host interplay during the course of EBOV infection
1.1.1 Ebola virus genome
EBOV posseses a single-stranded, negative sense RNA genome of ~19 kilobases
in size8. The genome encodes seven genes, each of which are individual transcriptional
units that encode seven viral structural proteins: Viral Protein 40 (VP40), Viral Protein 35
(VP35), Viral Protein 30 (VP30), Viral Protein 24 (VP24), Nucleoprotein (NP),
Glycoprotein (GP), and Large Protein (L) as shown in Figure 1A8. Transcriptional editing
of viral RNA results in the production of both a soluble form (sGP) and membrane-bound
form of GP, as well as an unedited sGP9. Each viral protein plays an important role during
the EBOV life cycle.
1.1.2 Ebola life cycle
EBOV enters the human cell via attachment and fusion mediated by viral surface
GP, which leads to viral internalization via macropinocytosis8,10,11. Acidification of the
endosome induces cleavage of GP by cellular cathepsins B and L, and subsequent binding
of GP to Neimann-Pick C1 (NPC1) in the late endosome10,12 . This allows for endosomal
fusion and the release of the viral genome into the cytoplasm, where viral transcription and
translation occur. Viral RNA synthesis begins on the uncapped, non-polyadenylated viral
template, which is converted to 5’-capped, polyadenylated mRNA by L protein13. VP35
acts to deliver L protein to the NP-encapsidated template by interacting with both L and
NP14. VP30 is also required for viral transcription and may play a role in the regulation of
the viral polymerase complex during transcription and replication15,16. The full-length
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complement of the RNA genome is used as a template to create new negative-sense RNA
genomes during replication8.

Following replication of the viral genome and transcription and translation of
EBOV proteins, viral particles are assembled along the plasma membrane. Virus release
occurs by budding and is mediated by the interaction of the main structural protein, VP40,
with members of the cellular Endosomal Sorting Complex for Transport (ESCRT)
pathway17,18. The N-terminal domain of VP40 promotes its own oligomerization, while a
hydrophobic patch within the C-terminal domain is responsible for penetration of
oligomerized VP40 into the inner leaflet of the plasma membrane19,20. The electrostatic and
hydrophobic properties of VP40’s carboxy-terminus induce plasma membrane attachment and
eventual VLP formation19.VP40 recruits ESCRT proteins Tsg101 and Nedd4, an ubiquitin

ligase, to the plasma membrane for budding. Tsg101 and Nedd4 act together to ubiquitinate
VP4017,18,21. The ubiquitinated form of VP40 is speculated to promote more efficient selfassembly, maturation and scission of viral particles from the plasma membrane21.
Filamentous virions emerge from the cell via two distinct modes; infectious particles
primarily bud horizontally, while less pathogenic empty virions bud vertically from the
cell22.

Each EBOV protein, other than sGP, is present in the fully formed enveloped viral
particle, but GP is the only protein that is exposed on the surface of viral particles. VP40
is the most abundantly produced of the seven proteins, and is the main structural protein
within viral particles. Specifically, VP40 forms the viral matrix between the genomeassociated nucleocapsid and lipid envelope to stabilize the virion shape19,23. Studies have
shown that VP40, in the absence of any other Ebola protein, can self-assemble into viruslike particles (VLPs)24–26. These particles are non-infectious and are morphologically
indistinguishable from natural Ebola virions, allowing studies of VP40 alone to be
representative of some aspects of EBOV replication26. A summary of the EBOV lifecycle
is shown in Figure 1B.
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Figure 1. Schematic of Ebola virus genome and lifecycle.
(A) The genome is shown in 3’ to 5’ orientation to indicate that it is negative-sense. NP,
nucleoprotein;

VP35,

viral

protein

35;

VP40,

viral

protein

40;

GP/sGP,

glycoprotein/soluble glycoprotein; VP30, viral protein 30; VP24, viral protein 24; L, Large
protein (the viral polymerase). (B) EBOV attaches to the cell surface via GP, and is taken
up by macropinocytosis. Upon acidification of the endosome, cathepsins B and L cleave
GP to allow for its interaction with NPC1 and fusion of the virus with the endosomal
membrane. The viral RNA is released into the cytoplasm where viral transcription and
replication occurs. VP30 is required for initial transcription of viral mRNAs, and genome
replication follows. RNA synthesis also requires NP, VP35 and L proteins. NP, VP35,
VP40, GP, VP30, VP24, and L are translated from the viral mRNAs and viral particles are
assembled at the plasma membrane. VP40, the viral matrix protein, directs budding and
VP24, GP and nucleocapsids are incorporated into the budding particles. Image retrieved
from Messaoudi et al. (2015) Nat Microbiol 13:663-768.
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1.2 Type I interferon response
The Type I IFN response is triggered by the presence of foreign pathogens such as
EBOV and is one of the body’s first innate defense mechanisms against viral infection27.
A summary of this response is shown in Figure 2. Recognition of foreign bodies induces a
downstream pathway leading to the expression of potent antiviral cytokines, most notably
IFNα and IFNβ28. The expression of IFNs is induced immediately following viral
recognition, and is essential in producing numerous cellular antiviral proteins that initiate
an antiviral state within the cell and signal for an antiviral state within neighboring cells.
IFNα and IFNβ are produced by almost every cell in the body, making them indispensable
for defense against viral infection28,29. Not surprisingly, mice deficient in the IFNα/β
receptor were severely impaired in resistance against numerous viruses including vaccinia
virus, vesicular stomatitis virus (VSV) and semiliki forest virus 30.
As a single-stranded RNA virus, EBOV is first recognized by the Type I IFN
response through the RNA helicase RIG-1 and Protein Kinase RNA-activated (PKR)31.
The downstream IFN cascade is activated, leading to dimerized IFN Regulatory Factor 3
(IRF3) and NFκβ translocation into the nucleus, where they act as a transcription factors
for Type I IFNs IFNα and IFNβ

32

(Figure 2). The release and binding of these IFNs to

their respective receptors (IFN Alpha Receptor; IFNAR) on neighboring cells causes an
association of the receptor with Tyk1 and Jak1 kinases. Tyrosine phosphorylation mediated
by these kinases activates STAT1 and STAT2 to interact with IRF9 and form the
transcription factor complex IFN Stimulated Gene factor 3 (ISG3)29. ISG3 translocates to
the nucleus and regulates the transcription of IFN stimulated genes (ISGs) via an
interaction with IFN stimulated response elements29. Interestingly, IRF7/IRF3
heterodimers amplify this response by acting as a transcription factor for IFNα and IFNβ
as shown in Figure 233.
1.2.1 Interferon stimulated genes
Many interferon-stimulated genes (ISGs) have been identified which target various
points of the viral lifecycle upon infection and stimulation of the Type I IFN response34. In
fact, over half of all early upregulated genes following EBOV infection of circulating
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immune cells were ISGs35. Some of the most upregulated genes include ISG15, Hect and
RCC-1-like domain containing protein 5 (HERC5), oligoadenylate synthase 1 (OAS1),
Interferon Induced Protein with Tetratricopeptide Repeats 2 (IFIT2), Interferon-induced
GTP-binding protein Mx1 (Mx1), and DExH-box helicase 58 (DHX58) – most of which
will be discussed further throughout this text35. Upon upregulation via stimulation of the
IFN response, ISGs create an antiviral state within the cell by performing antiviral defense
mechanisms that may target viral protein or viral RNA.
1.2.2 Antiviral activity towards viral protein
The antiviral defense mediated by ISGs are involved in viral protein modification,
degradation, and inhibition of protein translation. Viral proteins can be modified by
ubiquitin and sent to be degraded by protein degradation factors36,37. Most proteins are
targeted to the proteasome by covalent attachment of ubiquitin molecules. Proteasomes are
protein complexes which degrade unneeded or damaged proteins via proteolysis, a
chemical reaction in which the peptide bonds of the protein are broken38. The TRIM family
of proteins act as ubiquitin E3 ligases39. The ubiquitin ligase activity of the TRIM22 protein
in particular has been shown to be required for antiviral activity against viruses such as
encephalomyocarditis virus39.
PKR is also a highly upregulated ISG, as shown in Figure 2. In addition to being a
viral sensor upon initiation of the Type I IFN response, activation of PKR results in the
dimerization of inactive monomers which can then go on to inhibit the translation of new
viral proteins40. As a protein kinase, PKR phosphorylates the protein synthesis initiation
factor eIF-2α to achieve this antiviral activity40. This is important as viruses rely on the
host cell translation apparatus for expression of their proteins.
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Figure 2. Schematic of Type I interferon response to EBOV infection.
Left panel: recognition of the viral genome by PKR and RIG-I leads to the activation of
transcription factors NFκβ and IRF3, which translocate to the nucleus and activate the IFNβ
promoter. IRF-3 is phosphorylated to cause dimerization by IKKε and TBK-1, which are
activated by RIG-I, MDA5 and IPS-1/MAVS. Right panel: IFNβ binds to its receptor
IFNAR to cause the activation of the JAK/STAT pathway and eventual transcription of
ISGs. Mx, ISG20, OAS and PKR are examples of ISGs with antiviral activity. IRF7
amplifies the Type I IFN response by inducing the transcription of IFNα and IFNβ. The
various points by which EBOV proteins counteract the Type I IFN response are shown.
VP35, VP24 and GP are viral antagonists of the IFN response. More details regarding this
response and EBOV antagonism towards it can be found throughout the text. Image
retrieved from Haller et al. (2006) J Virol. 344: 119-13029.
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1.2.3 Antiviral activity towards viral RNA
The majority of well-characterized ISGs belong to a subset of proteins that affect
viral RNA; this may involve RNA modification or degradation. One RNA-editing enzyme
that is highly upregulated during the IFN response is ADAR1, an RNA-specific adenosine
deaminase41. Deamination of viral or cellular RNA makes it incompatible with cellular
machinery for further translation41. Additionally, OAS1 monomers oligomerize after
activation by the IFN response and produce 2’,5’-oligoadenylates which go on to activate
RNAse L, a ribonuclease that degrades both cellular and viral RNA42–44. Similarly, ISG20
is an ISG that acts to degrade viral RNA. ISG20 is an exoribonuclease that primarily acts
on single-stranded RNA viruses45.
An important ISG that drives selective destruction towards viral RNA, as opposed
to the broad-spectrum activities of the aforementioned enzymes, is the zinc finger antiviral
protein (ZAP). ZAP is known to recognize ZAP response elements (ZREs) within viral
mRNA, and cause downstream degradation by recruiting factors involved in RNA
degradation and inhibition of translation46–48. These include the deadenylase poly(A)
specific ribonuclease PARN, the RNA 3′-5′-directed exonuclease complex called the RNA
processing exosome, and the Dcp1/2 decapping enzymes through their p72 helicase cofactor46. Many viruses contain ZREs and are restricted by ZAP, including Human
Immunodeficiency Virus-1 (HIV-1), Sindbis virus, Murine gammaherpesvirus and
filoviruses47,49–51. In fact, ZAP has been shown to target and reduce mRNA levels of all of
the EBOV proteins, with L protein being affected the most50. The specific sequence of
ZREs remains elusive, though Takada et al (2017) found that high CG dinucleotide content
may be involved in ZAP recruitment52.
ZAP has four CCCH-type zinc fingers within its N-terminus, which are present in
both known human isoforms of ZAP: ZAP-long (ZAPL) and ZAP-short (ZAPS). These
zinc fingers are responsible for RNA binding48. Studies examining ZAP’s activity towards
EBOV utilize ZAP from rat cells (rZAP), which corresponds to human ZAPS (77 kDa) and
does not contain the C-terminal PARP domain that is present in ZAPL (101 kDa)50,53.
However, more recent research has found ZAPL to mediate stronger antiviral activity
towards viruses in general53.
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Interestingly, ZAP has been shown to act synergistically with other ISGs to mount
an antiviral response against viruses such as alphaviruses54. Although this study did not
determine the IFN induced factor that was responsible for the synergistic antiviral activity,
it was posited that ISG15 modifies ZAP or another member of the IFN response. ISG15 is
the most upregulated protein overall during the IFN response, and is a ubiquitin-like
molecule55. Given that ZAP is known to require ubiquitination by TRIM25 for optimal
binding to viral mRNA and antiviral activity, ISG15 may play a similar role in enhancing
ZAP’s activity56,57. In fact, ZAP is a known putative target for ISG15 conjugation by E3
ligases within the IFN response58.
1.3 Ebola restriction factors
Although many ISGs have been shown to be upregulated during the Type I IFN
response to EBOV infection, such as those outlined by Caballero et al (2016), the
mechanisms by which most of these proteins carry out their anti-viral roles remains
unclear35. The role the Type I IFN response as a whole plays towards EBOV infection is
quite elusive. However, a few ISGs have been identified as restriction factors specifically
towards EBOV in vitro. The fact that EBOV strongly inhibits the Type I IFN response
suggests that these restriction factors could potently restrict EBOV infection in vivo in the
absence of IFN antagonists encoded by the viral genome.
1.3.1 ISG15
ISG15 is one of the most upregulated genes during the Type I IFN response to most
viruses including EBOV, demonstrating its importance in the innate defense against viral
infection55. ISG15 is a ubiquitin-like molecule, which acts to modify proteins via a
mechanism called ISGylation. ISGylation occurs through a series of steps in which UbeL1
(E1) activates ISG15, and UbcH8 (E2) and an E3 ligase together conjugate the molecule
to substrates within the cell59,60. Common E3 ligases include the HECT and RCC-1-like
domain containing (HERC) and tripartite motif (TRIM) protein families61,62. ISGylation
plays a crucial role in restricting the replication of viruses such as Influenza A, HIV-1 and
EBOV63–66. During EBOV infection specifically, ISG15 inhibits the budding of VP40
VLPs. It does this by interacting with the E3 ligase Nedd4, which is required for the
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ubiquitination of VP40 prior to viral budding66. Free ISG15 acts to block an interaction
between the E3 ligase Nedd4 and its E2 counterpart, thereby preventing further
ubiquitination by Nedd466. Ultimately, such an interaction prevents the necessary
ubiquitination of VP40, and may suggest that ISGylation is also blocking the site of
ubiquitination. ISGylation of viral structural proteins to prevent viral assembly and release
is not unique to EBOV, and is seen with other viral structural proteins such as Influenza A
NS-1, HIV-1 Gag or Human Papillomavirus (HPV) L164,67,68. ISG15 plays other more
general antiviral roles including immune modulatory activity, prevention of viral defense
against IFNβ and increased susceptibility to viral infection when deficient69–71.
1.3.2 Interferon induced transmembrane proteins
IFN-induced transmembrane proteins, or IFITMs, inhibit entry of EBOV particles
by interfering with GP-mediated entry during the late stages of endosomal trafficking72.
IFITMs are a family of proteins that are primarily known for their IFN-mediated control of
Influenza A virus by targeting the entry process73. Although there has been less research
done on other viruses, EBOV is likely similarly targeted at the stage of viral fusion. This
is suggested by the fact that IFITM mediated restriction can be circumvented by
complementing cells with cathepsin L, which allows for the late stages of endosomal
compartment formation and viral fusion to occur72.
1.3.3 Tetherin
Tetherin is known to inhibit release of EBOV by preventing diffusion of viral
particles after budding74. It is a transmembrane protein known to bind viral and host
membranes, thereby preventing the release of viral particles by physically linking the viral
and cellular membranes75.

This proteinaceous covalent bonding results in the

accumulation or anchoring of viral particles along the plasma membrane, similar to the
well-characterized effect that tetherin has on HIV-176. In retroviruses, these particles
accumulate in a chain-like fashion and are ultimately re-internalized and subsequently
degraded within the cell76,77. Although tetherin’s activity towards EBOV is not as well
studied, it is predicted that degradation of particles occurs similar to retroviruses.
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For the vast number of IFN-induced proteins known to play a role in the Type I
IFN response, it is unfortunate that ISG15, IFITMs and tetherin are the only wellestablished proteins that target EBOV. Furthermore, all of these proteins are ultimately
antagonized by EBOV during an infection, giving rise to the overall suppression of the IFN
response and allowing severe pathogenesis to manifest. No antiviral restriction factors have
been identified which successfully circumvent EBOV infection. Investigating other IFNinduced proteins and their effect on EBOV is therefore important for better understanding
of the virus-host interplay during infection.
1.4 HECT and RCC-1 like domain containing protein 5 (HERC5)
One IFN-induced protein that warrants further investigation is HERC5. HERC5 is
known to inhibit the replication of evolutionarily diverse viruses including HIV-1,
influenza A, murine leukemia virus and HPV64,78,79. HERC5 is 1024 amino acids in length,
or ~117 kDa, and is ubiquitously expressed with highest expression levels in the testis80. It
is the main mammalian E3 ligase, meaning it conjugates the ubiquitin-like protein ISG15
to substrates within the cell.
HERC5 belongs to a family of six HERC proteins located on chromosome 4, each
containing an amino terminal Regulator of Chromosome Condensation 1 (RCC-1) like
domain (RLD), a spacer domain that does not share homology with any known proteins,
and a carboxyl terminal Homologous to E6-AP Carboxyl Terminus (HECT) domain
(Figure 3). The RLD domain and HECT domain are highly conserved through
evolutionarily diverse mammals, suggesting these domains play a fundamental role in
mammalian biology78,81. The RLD domain’s predicted structure closely resembles the
crystal structure of the human RCC-1 protein, with its seven-bladed β-propeller
structure64,82. This domain has been speculated to be responsible for HERC5’s localization
to polyribosomes translating novel proteins, and partially responsible for the ISGylation of
some proteins62,64. The HECT domain’s predicted structure is bi-lobed and is
predominantly responsible for the E3 ligase activity of the HERC family of proteins 64.
HERC5 in particular contains the active site for ISGylation at the Cys 994 residue located
within the HECT domain64. The HECT domain of HERC5 operates in conjunction with an
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activating E1 and conjugating E2 enzyme to transfer ISG15 to specific cellular substrates
through the ISGylation mechanism that has been previously explained64.
HERC5 broadly targets newly synthesized proteins as well as constitutively
expressed proteins involved in various cellular pathways, including RNA splicing,
chromatin remodeling, transcription, cytoskeletal organization, the stress response and
translation58,67,68,83–85. By associating with polyribosomes, HERC5 can target a wide
variety of proteins during their translation68. Several targets are also IFN induced proteins
involved in the antiviral response to foreign pathogens58,85. Regulation of HERC5
expression is hence necessary to avoid ubiquitous ISGylation of cellular components.
HERC5 expression is up-regulated in response to Type I IFNs in vitro and in vivo virus
infection, lipopolysaccharide, tumor necrosis factor α, and interleukin-1β78.
HERC5 inhibits viral replication through E3 ligase-dependent and -independent
mechanisms. Woods et al. (2011) has shown that HERC5 utilizes E3 ligase activity to
ISGylate the structural protein of HIV-1, Gag, in order to cause the restriction of viral
assembly and release64. HERC5 directly interacts with Gag and post-translationally
modifies it with ISG15, thereby causing arrest of an early stage of viral assembly at the
plasma membrane. This restriction was distinct from expression of ISG15 alone. HERC5
has also been shown to ISGylate the structural protein of Influenza, NS-1, to prevent
homodimer formation and corresponding host antagonism mediated by NS-163,67. HERC5
also ISGylates HPV L1 capsid protein to reduce viral infectivity of HPV pseudoviruses68.
On the other hand, Woods et al. (2014) has revealed an E3 ligase-independent
mechanism by which HERC5 restricts HIV-178. Quantitative PCR (qPCR) and
immunoprecipitation showed that HERC5 prevented nuclear export of viral RNA by
interrupting the Rev/RRE pathway in an RLD dependent manner78. Given the diverse viral
targets and various ways by which HERC5 can restrict viral replication, HERC5 may
restrict other viruses that have not been investigated, such as EBOV. Previous findings
showing that E3 ligases such as Nedd4 regulate EBOV egress lends support to this idea21.
As previously mentioned, HERC5 is also one of the most upregulated genes during EBOV
infection35.
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Despite upregulation of various IFN-induced antiviral proteins such as HERC5, it
should be noted that EBOV is still able to defeat the body’s defense mechanisms and cause
debilitating disease. Similar to the other identified IFN-induced restriction factors of
EBOV, any inhibitory activity mediated by HERC5 would likely be ablated in vivo due to
the potent suppression of the Type I IFN response mediated by EBOV.

Figure 3. Schematic of HERC5.
HERC5 is an E3 ligase of ~117 kDa in size. It contains an amino-terminal RLD domain
responsible for polyribosomal localization and restriction of some viruses by preventing
nuclear export of viral mRNA. The predicted β-propellor structure is shown below the
genomic representation of this domain. The carboxyl terminal HECT domain is responsible
for E3 ligase activity, with its active site at Cys 994 indicated by a yellow box. The
ISGylation capabilities of HERC5 are involved in restriction of HIV-1, Influenza A and
HPV pseudoviruses through ISGylation of their structural proteins. This domain has a
predicted bi-lobed structure shown below the genomic model. These two domains are
connected by a spacer domain that contains many α-helices but does not share structural
homology with any known proteins, and has no known function in HERC5’s activity.
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1.5 Ebola antagonism towards host
The severe pathophysiology of EBOV infection can be attributed to its potent
suppression of the IFN response. EBOV has been well documented to inhibit Type I IFN
production within a wide array of cell types including human umbilical vein endothelial
cells (HUVECs), peripheral blood mononuclear cells (PBMCs) and human monocytederived macrophages86,87. Studies in HUVECs showed that there was rapid expression of
pro-inflammatory cytokines during infection, but expression of IFN α and β was delayed
until 3 days post-infection86. This study also found that the formation of IFN-induced
transcription factor complexes, as well as the expression of important proteins within the
IFN pathway were reduced15. The absence of these IFN-induced genes is responsible for
depleting overall antiviral activity, and allows the severe pathogenesis of EBOV infection
to take form. Not surprisingly, antagonism of the IFN response by EBOV is associated
with increased virulence88. Genomic analysis by Kash et al. (2006) demonstrated that
infection of human liver cells with an Ebola strain with a lower replication rate (Reston)
resulted in increased activation of ISGs as compared to a highly replicating strain (Zaire)88.
This suggests that the Zaire strain is better able to evade the host immune response due to
Type I IFN suppression, resulting in decreased antiviral proteins and increased virulence.
The ability of EBOV to selectively inhibit the Type I IFN response suggests that
the IFN response harbors immune mechanisms that could ablate EBOV infection in the
absence of Ebola antagonists89. In fact, the difference between those who survived EBOV
infection and those who did not was found to be in their innate immune responses,
including the IFN response90,91. Moreover, the viral antigen load did not vary between
survivors and non-survivors, though the viral clearance by the innate immune system was
significantly higher for survivors90. Baize et al. (1999) showed that survivors of the 1966
outbreak in Gabon, Africa had increased levels of IFN mRNA as well as other innate
immune molecules such as IgG antibodies91. Ultimately however, EBOV outbreaks hold
up to 90% fatality rates due to its multifaceted ability to suppress the Type I IFN response.
The viral genome encodes seven accessory proteins, three of which play a known role in
this process.
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1.5.1 Viral protein 35
The VP35 protein functions as a powerful virulence factor, and is a major
contributor in shutting down the production of IFN-α/β92. It does this by interacting with
members of the RIG-1 pathway, one of the cascades depicted in Figure 2 that causes IFNα/β expression and is triggered after the RNA helicase RIG-1 senses the EBOV
genome32,92. Particularly, VP35 interacts with two IFN regulatory factor (IRF) 3 kinases,
IKKε and TBK-1, to prevent phosphorylation and activation of IRF393,94. IRF3 is a
transcription factor that is responsible for transcription of IFN- α/β93. Another way by
which VP35 shuts down the IFN response is by interacting with an E2 and E3 ligase, Ubc9
and PIAS1 respectively, in order to cause the conjugation of a small ubiquitin-like modifier
(SUMO) to IRF3 and IRF795. As functionally homologous transcription factors,
SUMOylation of IRF3/7 represses transcription of ISGs. Other mechanisms of IFN
suppression by VP35 include suppression of RNA silencing96, and inhibition of dsRNAactivated protein kinase (PKR), an IFN-induced dsRNA-activated cellular serine/threonine
kinase responsible for inhibiting viral replication31,96,97. VP35 alone provides a significant
virulence factor to the virus, though EBOV does contain other proteins to evade the Type
I IFN response.
1.5.2 Viral protein 24
VP24 is considered the secondary matrix protein involved in capsid formation, but
is also involved in virulence. Its primary role as a virulence factor is to prevent nuclear
accumulation of STAT1, which, when dimerized, is allowed to enter the nucleus and act
as a transcription factor for IFN-α/β and various ISGs98. Western blotting and coimmunoprecipitation techniques show that VP24 interacts with a member of the NP-1
family of proteins responsible for the import of dimerized STAT1 into the nucleus98. This
protein, karyopherin α1 (KPNA), is a nuclear localization signal receptor for dimerized
STAT1, which is inhibited by the interaction with VP24. Interestingly, VP24 uses mimicry
of STAT1 to bind to KPNA, rather than ablating the receptor’s activity, and is itself
imported into the nucleus99.
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1.5.3 Glycoprotein
GP potently prevents the activity of IFN-induced tetherin, through a mechanism
that has yet to be elucidated

74

. Using FACS analysis, Lopez et al. (2010) demonstrated

that, unlike other viral mechanisms to counter tetherin such as HIV-1 Vpu, GP does not
remove tetherin from the surface75. GP also did not require specific sequences within the
tetherin protein to cause restriction, suggesting that EBOV GP inhibits tetherin activity
through a novel mechanism75. Though studies have been inconclusive, it is possible that
GP relocalizes tetherin within the plasma membrane or interrupts the structural integrity of
the protein at filoviral budding sites. Radoshitzky et al (2010) observed that tetherin is
excluded from the plasma membrane in sites that contained EBOV GP during infection,
lending support to the idea that tetherin is relocalized in order to evade its tethering
mechanisms100.
1.6 Project rationale
In summary, EBOV is one of the most virulent pathogens that infects humans. Its
extreme pathogenesis can be largely attributed to evasion of the innate immune response6,8.
Specifically, EBOV is known to harbor various mechanisms to evade the Type I IFN
response, a response that triggers the production of antiviral proteins such as ISG15,
IFITMs and tetherin that create an abrasive environment for the virus within the cell6. For
example, accessory proteins VP35 and VP24 are known to interrupt ISG transcription at
numerous points92–94,96,98. GP is also known to prevent the activity of IFN-induced tetherin,
thereby allowing the budding and release of EBOV particles74,75. The potent suppression
of the IFN response by EBOV suggests that this defense mechanism would be effective in
preventing viral replication in the absence of appropriate antagonists.
It is important for future studies to investigate the interplay between EBOV and the
human host to further characterize the Type I IFN response and Ebola’s activity against it.
It is likely that additional IFN induced proteins such as HERC5 act as antiviral proteins
against EBOV infection, and that EBOV encodes appropriate antagonists. As
aforementioned, HERC5 restricts various viruses using mechanisms that may or may not
involve its E3 ligase activity64,67,68,78. It is possible that HERC5 uses its E3 ligase activity
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to ISGylate the structural protein of EBOV, VP40, similar to HIV-1, Influenza A or HPV64.
Previous research showing that ISGylation of VP40 prevents viral release suggests that an
E3 ligase is involved in the process65,66; HERC5 may be conjugating ISG15 to prevent
VP40 VLP release. Alternatively, HERC5 may use an entirely novel defense mechanism
to restrict EBOV, as the Spacer domain remains uncharacterized and the RLD domain has
been recently discovered to be involved in a unique E3-ligase independent antiviral
mechanism against HIV-178.
HERC5 may cause downstream antiviral events against EBOV, such as degradation
of viral protein, inhibition of translation or degradation of viral RNA. A major factor
already known to be involved in reducing EBOV RNA levels within an IFN stimulated cell
is ZAP50. ZAP is known to act synergistically with other IFN induced proteins, and is
known to be activated by ubiquitination – a molecule resembling ISG1554,56,57. Considering
ZAP is a putative target for HERC5 ISGylation58, HERC5 may utilize the ZAP pathway to
mediate its restriction. The potential for HERC5’s involvement in the IFN response against
EBOV infection has driven the initiation of this project, and lead to my hypothesis.
1.7 Hypothesis and specific aims
The overall objective of this project was to determine if HERC5 mediates antiviral
activity towards EBOV. I hypothesized that, given the evolutionarily diverse set of viruses
that HERC5 restricts, it would also restrict EBOV and that one or more of the genes
encoded by EBOV would antagonize HERC5’s restriction capabilities.
To address this hypothesis I have four major specific aims: 1) Develop a model
system of EBOV in order to study its replication. 2) Determine if HERC5 can mediate
antiviral activity towards EBOV. 3) Characterize the mechanism by which HERC5
mediates restriction. 4) Determine if one (or more) of the EBOV proteins antagonize
HERC5-mediated activity. The goal of this research is to further the understanding of the
virus-host interplay between EBOV and their human host counterparts, and advance the
current understanding of HERC5’s role in the innate immune response to viral infection.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Cells and cell lines
Adherent 293T human fibroblast and HeLa cells were maintained in complete
Dulbecco’s Modified Eagle’s Medium (cDMEM) (10% FBS, 1% Pen Strep (Sigma) in
DMEM) at 37°C with 5% CO2. Cell lines were obtained from American Type Culture
Collection.
2.2 Plasmids, transfections and antibodies
A summary of the plasmids and RNAs used in this study and their sources can be
found in Table 1. Note that pCR2.1-GP was restriction digested using HindIII and XBaI,
and GP was inserted into pCMV3xFLAG using T4 Ligase according to manufacturer’s
instructions (New England BioLabs). VP24 was unable to be cloned into a mammalian
expression vector (ie. pCMV3xFLAG). pEGFP-VP40 and pFLAG-VP40 were cloned
using the Gibson Assembly Master Mix kit (New England BioLabs) and the primers listed
in Table 2. HERC5 mutants (HERC5-RLD-only and HERC5-ΔHECT) were constructed
using site-directed mutagenesis (primers listed in Table 2), and cloned according to
instructions in the Fast Cloning protocol described by Li et al. (2011)12.
Unless

otherwise

stated,

plasmid

transfections

were

performed

using

Lipofectamine 2000 (Invitrogen) or LipoD (Invitrogen) according to manufacturer’s
instructions at a ratio of 1:10 for VP40:GL3/HERC5/ HERC5-ΔRLD/ HERC5-RLDonly/HERC5-ΔSpacer/HERC5-ΔHECT/HERC5-C994A (restriction assays) or 1:10:10 for
VP40:GL3/HERC5:GL3/VP30/VP35/L/NP/GP (antagonist assays).
Knockdown of HERC5 using small interfering RNA (siRNA) was performed using
Lipofectamine RNAiMAX (Life Technologies) transfection at a final concentration of 40
pM siRNA/sample as per the manufacturer’s instructions. Knockdown of HERC5 using
short hairpin RNA (shRNA) was performed by transfecting HERC5shRNA (or ScramshRNA)
with Lipofectamine 2000 at a ratio of 10:1 with VP40 and IFNβ (PBL Assay Science)
inducing at 1000U/mL for 24h before harvesting. Knockdown of ZAP using shRNA was
performed by transfecting ZAPshRNA (or ScramshRNA) 48h before transfection with HERC5
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and VP40 (ZAPshRNA/ScramshRNA:GL3/HERC5:VP40 10:10:1). 24h later, IFNβ induction
at 1000U/mL was performed and harvested after another 24h. For the MG132 assay
determining the effect of proteasome inhibition, 20 µM MG132 (Sigma) was added to
culture supernatant at 32 hours post-transfection, and cells were treated for 16 hours before
harvesting.
Antibodies: anti-FLAG was obtained from Sigma, anti-GFP from Clontech, antiGAPDH from EMD Millipore Corp., and anti-ZAP from Abcam.
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Table 1. Summary of plasmids and RNAs used in this study
Name(s)

Details

Source

pCAGGS-VP40
pCAGGS-VP30
pCAGGS-VP35
pCAGGS-L
pCAGGS-NP

Mammalian expression vectors encoding Dr.Yoshihiro
Ebola proteins as indicated; Amp
Kawaoka*

pCR2.1-VP24
pCR2.1-GP

Bacterial expression vector encoding Ebola Dr.Yoshihiro
VP24 or GP as indicated; Amp
Kawaoka*

pC-T7Pol

Mammalian expression vector encoding T7 Dr.Yoshihiro
polymerase; Amp
Kawaoka*

p3E5EGFP

Mammalian expression vector encoding GFP Dr.Yoshihiro
in the antisense direction, under T7 polymerase Kawaoka*
promoter; Amp

pEGFP-VP40

Mammalian expression vector expressing This study
VP40 with GFP fused to the carboxy-terminus;
Kan

pCMV3xFLAG-VP40
pCMV3xFLAG-GP

Mammalian expression vector expressing This study
indicated viral protein; Amp

pCMV3xFLAGHERC5
pCMV3xFLAGHERC5-C994A

Mammalian expression vector expressing Dr. K. Chin†
HERC5 or an E3 ligase active site mutant
(C994A); Amp

pCMV3xFLAGHERC5-ΔRLD
pCMV3xFLAGHERC5-ΔSpacer

Mammalian expression vector expressing Dr. Matthew
indicated HERC5 mutant; Amp
Woods‡

pCMV3xFLAGHERC5-RLD-only
pCMV3xFLAGHERC5-ΔHECT

Mammalian expression vector expressing This study
indicated HERC5 mutant; Amp
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pGL3

Empty promoterless vector; Amp

pCMV3xFLAG

Mammalian expression vector for expression Sigma
of
amino
terminally 3xFLAG-tagged
proteins;Amp

peGFP –N1
peGFP-C1

Mammalian expression vector for fusing Dr.Bryan
EGFP to the carboxy or amino terminus of a Heit‡
partner protein; Kan

pCMV-Sport6-ZAP

Mammalian expression vector expressing Dharmacon
ZAPS (ZC3HAV1, zinc finger CCCH-type
containing, antiviral 1); Amp

pLKO.1/ZAP-1shRNA
pLKO.1/ZAP-2shRNA

Mammalian expression vector expressing Dharmacon
short
hairpin
RNA
targeting
ZAP
(ZC3HAV1); Amp

HERC5-1siRNA
HERC5-2siRNA
ControlsiRNA

Small interfering RNA targeting HERC5 or a Thermo
scrambled sequence (control)
Fisher

pLKO.1/H5-1shRNA
pLKO.1/H5-2shRNA
pLKO.1/ScramshRNA

Mammalian expression vector expressing Addgene
short hairpin RNA targeting HERC5 or a
scrambled sequence; Amp

* University of Wisconsin, USA
†
Genome Institute of Singapore, SG
‡
Western University, CA

Promega
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Table 2. Oligonucleotide primers used for cloning
Name

Sequence*

VP40-F

CGCTACCGGACTCAGATCTATGGCTGCTAGGCGGGT
TATATTG
GACCGGTGGATCCGGCTTCTCAATCACAGCTGGAAG
ACTTG
CCGGATCCACCGGTCGC
CATAGATCTGAGTCCGGTAGCGCTAG

VP40-R
EGFP-F
EGFP-R

Used for Gibson cloning VP40 into pEGFP
VP40-F
VP40-R
FLAG-F
FLAG-R

AATTCATCGATAGATCTGATGGCTGCTAGGCGGG
GTCGACTGGTACCGATATTTACTTCTCAATCACAGCT
GGAAG
ATATCGGTACCAGTCGACTCTAG
CAGATCTATCGATGAATTCGCGG
Used for Gibson cloning VP40 into pCMV3xFLAG

HERC5-ΔHECT-F
HERC5-ΔHECT-R
HERC5-RLD-only-F
HERC5-RLD-only-R

TTGATCTATGAAGAAGCGCTTCAAGAAG
CTTCTTCATAGATCAAACGTGGGCCTC
GCCATACCTCAGAAAAGGAGTTAATATAGATTGCTG
GAGGGAA
TTCCCTCCAGCAATCTATATTAACTCCTTTTCTGAGG
TATGGC
Used for site-directed mutagenesis of HERC5-ΔHECT and
HERC5-RLD-only

* All oligonucleotides are in 5’ to 3’ orientation
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2.3 Western blotting
Clarified cell supernatants containing VLPs were pelleted over a 20% sucrose
cushion for 2 hours at 21,000 × g. For cell lysates, cells were detached and centrifuged at
1500 × g for 5 mins. Pellets were lysed with 1× RIPA buffer (50mM Tris-HCl (pH 7.4),
150 nM NaCl, 1 mM EDTA, 1% Protease Inhibitor Cocktail (Sigma), 1% 100mM
phenylmethanesulfonyl fluoride in isopropanol, 1% TritonX-100, 0.1% SDS). For
quantitative Western blotting, samples were mixed with 4× loading buffer (40% Glycerol,
240 mM Tris/HCl pH 6.8, 8% SDS, 0.04% bromophenol blue, and 5% betamercaptoethanol) to a final 1× concentration and separated on a 10% SDS-PAGE gel.
Protein was transferred onto 0.2µm Low Fluorescence Amersham Hybond Polyvinylidene
difluoride (PVDF) membrane (GE Healthcare Life Sciences) by semi-dry transfer. Western
blotting was carried out by blocking the membrane for 1 hour in Li-cor Blocking Buffer
(Li-cor Biosciences) followed by a ~16 hour incubation with 1:1000 dilution of primary
antibody. Detection was carried out using IRdye-labeled secondary antibody (1:20,000 for
1 hour) and the Li-cor Odyssey Clx Detection System (Li-cor Biosciences). Densitometric
analysis was performed using ImageJ 1.48 u 64-bit version software (NIH, USA).
2.4 RNA isolation and reverse transcription polymerase chain reaction
Total RNA was isolated from cell lysates using the Purelink RNA Mini Kit and
reverse transcribed using M-MLV reverse transcriptase according to manufacturer's
instructions (Life Technologies). 40ng of cDNA was used as template for quantitative realtime polymerase chain reaction (qRT-PCR) reactions using gene specific primers listed in
Table 2 and the SYBR Probe Master Mix (Qiagen). qRT-PCR was carried out using
QuantiStudio5 Applied Biosystems with the following specifications: 2 min at 50°C, 10
min at 95°C and 40 cycles of 15 sec at 95°C and 60 sec at 60°C (Thermo Fisher Scientific).
Threshold cycle (CT) values for RNA were normalized to the CT values of GAPDH and
relative fold changes were calculated using the Pfaffl Equation.
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Table 3. Oligonucleotide primers for quantitative PCR*
Gene

Forward Sequence

Reverse Sequence

VP40

GCTTCCTCTAGGTGTCGCTG

GGTTGCCTTGCCGAAATGG

VP30

CCAGACAGCATTCAAGGG

GCTGGAGGAACTGTTAATGG

VP35

CGACTCAAAACGACAGAATG

GGTTTGGCTTCGTTTGTTGC

C
NP

GCCAACTTATCATACAGGCC

CCAAATACTTGACTGCGCC

L

CCTAGTCACTAGAGCTTGCG

GGCTCAACAGGACAGAATCC

GP

GTGAATGGGCTGAAAACTGC

CCGTTCCTGATACTTTGTGC

HERC5

GATGACGATGACAAGATGGA

ACTTCGTCTGACTCTTAGATCAA

GCGCCGCAGC

ACGTGGGCCTC

CGCTTAATGGTAGCTGCAGC

CCTACAGAACAGAGGTGGATTC

ZAP

C
GAPDH

CATGTTCGTCATGGGTGTGAA

AGTGATGGCATGGACTGTGGTC

CCA

AT

*All oligonucleotides are in 5’ to 3’ orientation
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2.5 Confocal immunofluorescence microscopy
HeLa cells were cultured in 12-well plates on 18 mm coverslips and co-transfected
with either pHERC5, pGL3 and pEGFP-VP40 (10:10:1 ratio) or pHERC5, pZAP and
pEGFP-VP40 (10:10:1 ratio). Twenty-four hours after transfection, coverslips containing
cells were washed twice with PF buffer (1× PBS + 1% FBS), fixed for 10 minutes in 1×
PBS containing 5% formaldehyde and 2% sucrose, permeabilized in 1× PBS containing
5% NP-40 and then washed twice more with PF buffer. Coverslips were incubated with
either primary antibody mouse anti-FLAG (1:500 dilution) or rabbit anti-ZAP (1:500) for
1 hour, washed 3x with PF buffer and incubated with either secondary antibody anti-rabbit
488 (1:10000 dilution) or anti-mouse 594 (1:1000) for 1 hour. Coverslips were washed 3x,
incubated in Hoechst 33342 (1:10000 dilution) (Life Technologies) for 5 mins and washed
6x with PF buffer. Coverslips were then mounted on glass slides with 10 µL Vectashield
mounting media (Vector Laboratories Inc.) and sealed with nail polish. Confocal
micrographs were obtained using a Leica TCS SP8 (Leica Microsystems) microscope, and
Leica Application Software X was used for image acquisition, Pearson’s coefficient and
Mean Fluorescence Intensity calculations.
2.6 Transmission electron microscopy
293T cells were co-transfected with pGL3 or pHERC5 and pEGFP-VP40 at a 10:1
ratio. After 48 hours, cells were resuspended in media, fixed in 2.5% glutaraldehyde in
0.1M sodium cacodylate (pH 7.4) for 2 hours, and washed 3x in 0.1M sodium cacodylate.
Cells were pelleted and fixed with 2% osmium tetroxide in sodium cacodylate. After ~1
hour in the dark, cells were washed 3x in ddH2O. Cells were pelleted again, water was
discarded and samples were left at 4°C overnight. Dehydration of samples was carried out
by adding 1 mL 20% acetone in ddH2O, mixing and incubating 10 min at RT. Cells were
pelleted, acetone was removed and procedure was repeated with 50%, 70%, 90%, 100%,
100% and 100% acetone. Cells were embedded in resin by adding 1 mL of a 2:1 mix of
acetone:resin (Epon) and incubating for ~4hrs at RT in a rotating tube shaker. Cells were
pelleted, acetone:resin mix was discarded and this was repeated with a 1:1 mix overnight,
1:2 mix overnight and finally only resin overnight. Samples were cut in 70 nm slices using
a Sorval Ultracut ultramicrotome, and placed onto 400 mesh nickel grids (Embra). Grids
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were placed on drops of 2% uranyl acetate in ddH2O to stain for 20 mins in the dark, and
washed 5-6x in ddH2O for 1 min. Samples were then stained in drops of Sato’s lead citrate
(5 mM calcined lead citrate, 11 mM lead nitrate, 11 mM lead acetate, 95 mM sodium
citrate) for 1 min and washed using ddH2O. NaOH pellets were placed beside each sample
during lead staining to eliminate lead citrate exposure to atmospheric CO2 and therefore to
prevent its precipitation. Samples were then imaged using a Phillips CM10 Transmission
Electron Microscope. AMT Advantage digital imaging system was used for image
acquisition.
2.6.1 Immunogold transmission electron microscopy
293T cells were fixed, embedded in resin, cut and placed onto grids as previously
explained. Grids were blocked with a 0.2 uM filtered 1% BSA PBS Buffer (10.4 mM
Na2HPO4, 3.2 mM KH2PO4, 20 mM NaN3, 150 mM NaCl, 1% BSA, pH 7.4) and incubated
at room temperature for 2 hours with 0.25 mg/ml mouse anti-GFP (1:20 dilution). Samples
were washed and incubated at room temperature for 2 hours with secondary goat antimouse IgG colloidal 5 nm gold-conjugated antibody (Frogga cat# GA1003) at a dilution
of 1:30. Samples were washed with BSA-PBS buffer and then with dH20. Samples were
stained with 2% uranyl acetate for 5 minutes and then washed with dH20. Samples were
imaged using a Phillips CM10 Transmission Electron Microscope. AMT Advantage digital
imaging system was used for image acquisition.
2.7 Co-immunoprecipitation
Co-immunoprecipitation of pFLAG was performed using the µMACs antiDYKDDDDK kit according to manufacturer’s instructions. Briefly, 293T cells were lysed
using Lysis Buffer (150 mM NaCl, 1% Triton® X-100, 50 mM Tris HCl pH 8.0, 1%
Protease Inhibitor Cocktail (Sigma)) for 30 min on ice. 50µL (per 10cm dish of 293T cells)
anti-DYKDDDDK microbeads were mixed with lysed 293T cells to magnetically label
FLAG tagged proteins. Lysate was run through a magnetic column and washed 4x with
Wash Buffer 1 (150 mM NaCl, 1% Igepal CA-630 (formerly NP-40), 0.5%
sodiumdeoxycholate, 0.1% SDS, 50 mM Tris HCl pH 8.0) and 1x with Wash Buffer 2 (20
mM Tris HCl pH 7.5). Protein was eluted with pre-heated (95ºC) 50µL Elution Buffer (50
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mM Tris HCl (pH 6.8), 50 mM DTT, 1% SDS, 1 mM EDTA, 0.005% bromphenol blue,
10% glycerol).
2.9 Statistical analyses and bioinformatics
GraphPad Prism v4.03 was used for all statistical analyses. P values and statistical
tests were stated where appropriate. P values less than 0.05 were deemed significant.
2.10.1 Immunogold labelling quantification
Quantification of immunogold particle localization was performed as previously
described101. Gold particles were counted for four fields of view per condition and scored
as one of three regions: 1) Ebola VLPs and plasma membrane; 2) cytoplasm and nucleus;
and 3) not containing particles or cells. The plasma membrane was defined as the outer
most edge of the cell to a distance 100 nm inside the cell (approximately the diameter of
an Ebola VLP2). This numerical frequency distribution (G0) represents the 'observed'
distribution102. The 'expected' or 'predicted' distribution was determined using a randomly
positioned lattice of test points (P) superimposed on each field of view using the ‘grid’
feature in Adobe Photoshop CS3. The resulting distribution of test (or 'grid') points shows
what would be expected if gold particles were scattered randomly across the cell102. The
number of points that fell on each of the three regions of interest were scored. The expected
number of gold particles (Ge) for each region was calculated using the formula: Ge =
P*(total Go)/(total P). The corresponding partial X2 for each region was calculated from the
observed and expected gold counts as: X2 = (Go-Ge)2/Ge. If the total X2 value for the given
degrees of freedom (df) (given by 2-1 columns × 3-1 regions) indicated that the observed
and expected distributions were significantly different, the null hypothesis of no difference
from random labeling was rejected. Preferentially labeled regions were identified on the
basis of satisfying two criteria. First, the Go/Ge was > 1 and, secondly, the corresponding
partial X2 value accounted for a substantial proportion (≥ 10%) of the total X2 value102.
2.10.2 CG dinucleotide content
CG content of EBOV sequences was calculated by counting the number of CG
dinucleotides in a 200 base pair sliding window of each viral cDNA sequence and a random
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sequence, as shown by Muller et al. (2007)50. Coding sequences for each Ebola protein can
be found in Appendix A.
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CHAPTER 3: RESULTS
3.1 Construction and verification of EBOV VP40 VLP assay
In order to measure and visualize HERC5’s effect on EBOV VLP production, we
aimed to generate a GFP fusion protein with structural protein VP40. 293T cells were
transfected with constructs encoding VP40 with N-terminal GFP (pEGFP-VP40-C1), or
C-terminal GFP (pEGFP-VP40-N1) (Figure 4A). Western blot analysis of VP40 VLPs
showed that VLPs were released into the supernatant of EGFP-VP40-C1 expressing cells
but not EGFP-VP40-N1 expressing cells (Figure 4B). The band showing GFP-VP40
immunoreactivity appeared at ~65kDa, consistent with the fusion of the 40kDa VP40
protein with the 29kDa EGFP protein. To further investigate assembly and budding of the
GFP-VP40 VLPs we performed confocal fluorescence microscopy and transmission
electron microscopy (TEM). Confocal micrographs of HeLa cells expressing EGFP-VP40C1 displayed punctate fluorescent GFP-VP40 bodies localized at the plasma membrane
consistent with budding of VLPs (Figure 4C), whereas EGFP-VP40-N1 expressing cells
showed GFP-VP40 evenly distributed throughout the cytoplasm (Figure 4C).
Transmission electron micrographs of 293T cells expressing EGFP-VP40-C1
displayed efficient VLP release when compared to an unperturbed membrane of a “mock”
transfected cell (Figure 4D). VLPs appeared as both spherical electron dense cross sections
~ 100 nm in diameter, and as elongated filamentous cross-sections ~300 nm in length.
Filamentous VLPs were protruding vertically from the membrane, as depicted in the
schematic representation of vertical budding in Figure 4E15. Successful budding of VLPs
at the plasma membrane by EGFP-VP40-C1 allowed us to utilize this plasmid for further
experiments involving EBOV VLPs.
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Figure 4. Plasmid containing GFP tagged VP40 at the N-terminus caused budding
similar to wild type EBOV.
(A) Plasmid constructs expressing N-terminus or C-terminus GFP-tagged VP40. (B)
Detection of GFP-VP40 VLPs in cell supernatant by Western blot using anti-GFP for
EGFP-VP40-C1 or EGFP-VP40-N1 transfected 293T cells. (C) Confocal micrographs
showed GFP-VP40 fluorescent bodies localized at the plasma membrane in HeLa cells 48
hours after transfection with EGFP-VP40-C1. GFP-VP40 was spread evenly throughout
the cytoplasm of HeLa cells 48 hours after transfection with EGFP-VP40-N1. Scale bars =
10µm (D) Transmission electron micrographs showed unperturbed membrane of 293T
cells “mock” transfected, and VLP release in 293T cells transfected with EGFP-VP40-C1.
Bottom panels of micrographs are zoomed images of the black boxes in the upper images.
Scale bars = 500 nm. (E) Schematic representation of vertical (left) and horizontal (right)
budding of EBOV (Takada 2012)15.
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3.2 HERC5 potently blocks the release of EBOV VP40 VLPs at the plasma
membrane
To determine the phenotypic effect of HERC5 expression on VP40 production we
used both confocal and transmission electron microscopy (TEM)(Figure 5). In Figure 5A,
HeLa cells co-expressing GFP-VP40 and empty vector depicted punctate fluorescence at
the plasma membrane, consistent with the location of budding GFP-VP40 VLPs. However,
cells co-transfected with GFP-VP40 and HERC5 lacked VP40 punctate fluorescence at the
plasma membrane, suggesting an inhibition of VLP production and release (Figure 5A).
Transmission electron micrographs of 293T cells co-transfected with GFP-VP40 and
empty vector also had a perturbed plasma membrane and spherical electron dense crosssections of VLPs ~100 nm in diameter (Figure 5B). Cells co-transfected with GFP-VP40
and HERC5 showed substantially less VLPs compared to the control and displayed a
smooth plasma membrane similar to mock transfected cells (Figure 5B). VLP production
was quantified using immunogold TEM in which 293T cells were transfected, prepared for
TEM and stained using a gold-tagged antibody targeting GFP (Figure 5C). HERC5
transfected cells exhibited significantly fewer immunogold particle counts as compared to
control (Figure 5D) (P<0.01, student’s T test). It is interesting to note that some VLPs were
produced in HERC5-transfected cells, however these particles appeared to be trapped at
the plasma membrane as indicated with arrows shown in Figure 5B and Figure 5C.
To confirm that VP40 protein accumulated in EBOV VP40 particles and electron
dense regions at the plasma membrane, we performed localization studies of immunogold
particles. Quantification of immunogold localization on the electron microscopic thin
sections from cells expressing HERC5 and VP40 showed that the gold labeling distribution
was significantly different from a random distribution (Chi square analysis, X2 = 314.8, df
= 2, P < 0.0001) (Table 4) (see Methods for details). The VP40 was primarily localized
along the plasma membrane, though VP40 was also found within VLPs that were formed
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Figure 5. HERC5 blocks VP40 VLP formation along the plasma membrane
(A) Confocal micrographs of HeLa cells that were co-transfected with GFP-VP40 and
either empty vector (control) or HERC5. Anti-GFP was used to detect GFP-VP40, and
anti-Flag was used to detect HERC5. Scale bar = 10µm (B) Transmission electron
micrographs of 293T cells that were “mock” transfected, transfected with empty vector
(control) and VP40, or transfected with HERC5 and VP40. Bottom panels of micrographs
are zoomed images of the black boxes in the upper images. Scale bar = 500nm (C)
Micrographs of cells that were transfected with empty vector and immunogold labelled
VP40, or HERC5 and immunogold labelled VP40. Gold particles are 5 ± 2 nm in size.
Scale bars = 500 nm. (D) Quantification of immunogold particles. *** P<0.001, **P<0.01,
*P<0.05. Student’s paired T-test.
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in the presence of HERC5 (Table 4). The localization of VP40 along the plasma membrane
and within VLPs was also seen in control cells, as expected (Table 5).
3.3 HERC5 potently restricts EBOV VP40 protein
Given the drastic effect HERC5 showed towards VP40 VLP production using
microscopy, we next wanted to look at the protein levels of VP40. We co-transfected 293T
cells with 0.15 µg EBOV VP40 and increasing amounts of HERC5 (0 µg, 0.38 µg, 0.75 µg
and 1.50 µg), followed by Western blot analysis of VP40 levels. In Figure 6A, cells cotransfected with HERC5 showed a dose-dependent reduction in VP40 protein with
increasing HERC5. The highest restriction was seen when HERC5 was transfected at a
10:1 ratio to VP40, with a 2.51-fold reduction in VP40 protein. (P<0.01, one-way ANOVA
with post-hoc Dunnet’s square). Similarly, a dose-dependent pattern of HERC5-mediated
restriction occurred with VP40 VLPs released into the supernatant (Figure 6B), with a
potent 6.67-fold reduction when HERC5 was transfected at a 10:1 ratio with VP40. This is
consistent with the reduction in VP40 VLPs as shown through immunogold TEM
quantification. To confirm HERC5’s responsibility for the reduction in VP40 protein
levels, we used HERC5shRNA to knockdown endogenous levels of HERC5 within 293T
cells (knockdown efficiency found in Appendix B). 1.5µg of HERC5shRNA was cotransfected with 0.15µg of FLAG-VP40. Western blot analysis showed that intracellular
VP40 levels were increased 1.52-fold, while VP40 VLP levels were increased 1.69-fold
when HERC5 was absent (Figure 6C).
3.4 Protein degradation is not involved in HERC5-mediated restriction of VP40
To better understand the mechanism of how HERC5 reduces intracellular levels of
VP40, we asked if HERC5 induces degradation of VP40 via the 26S proteasome complex,
the major complex involved in protein degradation within the cell38. We co-transfected
293T cells with EGFP-VP40 and empty vector or HERC5, and 20 μM of 26S proteasome
inhibitor MG132 was used to treat cells for 16 hours before VLP purification. Without
MG132, significantly decreased VP40 levels were shown in the supernatant (P<0.0001,
student’s paired t test) and cell lysate (P<0.0001, paired t test) in the presence of HERC5
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Table 4. Quantification of 5nm gold particle labelled anti-GFP in cells expressing
HERC5 and VP40
Region

Particles +
plasma
membrane
Cytoplasm
+ nucleus
Non-particle
+ non-cell
TOTAL

G0/Ge

X2

X2 as
%

15

Expected
gold count,
Ge
4

7.75

176.43

66.94

35

49

13

0.71

39.62

15.03

1

192

53

0.02

47.52

18.02

70

256

70

263.57

100

Observed
gold count,
G0
30

Point
count, P

For X2= 176.43 and df=2, P <0.0001 (X2 analysis). The gold labeling distribution is
significantly different from random. Only the particles/plasma membrane region
(Go/Ge= 7.75, X2= 66.9% of total) meets the two criteria for being preferentially labeled
((Go/Ge) ≥ 1 and X2 > 10% of total).
Table 5. Quantification of 5nm gold particle labelled anti-GFP in cells expressing
empty vector and VP40
Region

Particles +
plasma
membrane
Cytoplasm +
nucleus
Non-particle
+ non-cell
TOTAL

Observed
gold count,
G0
112

Point
count, P

Expected gold
count, Ge

G0/Ge

X2

X2 as
%

17

14

7.73

656.78

79.28

99

64

55

1.82

36.33

4.39

7

175

149

0.05

135.35

16.34

218

256

218

828.46

100

For X2= 656.78 and df=2, P <0.0001 (X2 analysis). The gold labeling distribution is
significantly different from random. Only the particles/plasma membrane region
(Go/Ge= 7.73, X2= 79.3% of total) meets the two criteria for being preferentially labeled
((Go/Ge) ≥ 1 and X2 > 10% of total).
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Figure 6. HERC5 restricts EBOV VP40 protein
(A) HERC5 reduces intracellular VP40 protein levels in a dose-dependent manner.
Representative Western blot of three independent trials is shown. Western blots were
densitometrically analyzed using anti-FLAG and anti-GAPDH. N=3. (B) HERC5 reduces
VP40 VLP release into supernatant in a dose-dependent manner. Representative Western
blot of three trials is shown. Western blots analyzed using anti-FLAG and anti-GAPDH.
N=3. (C) HERC5 knockdown rescues VP40 protein. 293T cells were co-transfected with
ScramshRNA or HERC5shRNA and FLAG-VP40. Forty-eight hours after transfection, EBOV
VP40 VLPs released into the supernatant and intracellular protein were analyzed via
Western blot using anti-FLAG and anti-GAPDH. N=3. *** P<0.001, **P<0.01, *P<0.05.
One way ANOVA with post-hoc Dunnet’s square for A-B, paired T-test for C. All data are
representative of at least three independent experiments (N).
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(Figure 7A-C). HERC5 also significantly decreased VP40 levels within the supernatant
(P<0.0001, student’s paired t test) and cell lysate (P<0.05, student’s paired t test) in the
presence of MG132 (Figure 7A-C). There was no significant difference in VP40 levels
between cells expressing HERC5 alone and cells expressing HERC5 with MG132
treatment.
3.5 HERC5 restricts VP40 mRNA
HERC5-mediated restriction at the protein level corresponded with a drastic
reduction of VP40 at the mRNA level as measured using qPCR. Cells expressing HERC5
showed an 8.93-fold reduction in EBOV VP40 mRNA (Figure 8A)(P<0.0001, student’s
paired T test). VP40 mRNA levels following HERC5 depletion using HERC5siRNA
(knockdown efficiency shown in Appendix B) exhibited a 2.04-fold increase (Figure
8B)(P<0.05, student’s paired T test). We showed that HERC5-mediated restriction is
specific to VP40 mRNA by investigating mRNA levels of a control gene (GFP) after
HERC5 co-transfection. GFP mRNA levels were not significantly different from control
when HERC5 was present (Figure 8C). HERC5 was also specific to VP40 independent of
its plasmid backbone. HERC5 mediated significant restriction towards VP40 mRNA when
co-transfected with either FLAG-VP40 or EGFP-VP40 (Figure 8C)( P<0.001, one-way
ANOVA with post-hoc Dunnet’s square). This allowed us to use EGFP-VP40 for
microscopy, and FLAG-VP40 for most other experiments.
Given HERC5’s potent restriction of EBOV VP40, we also wanted to see if this
restriction was specific to VP40, or whether HERC5 can also restrict the expression of
other EBOV genes. We co-transfected cells with either empty vector and one of VP40,
VP30, VP35, L, NP or GP at a 10:1 ratio, or with HERC5 and one of the aforementioned
proteins at the same ratio. Interestingly, HERC5 was able to significantly reduce all of the
EBOV mRNAs, but VP40 was reduced to the greatest extent (P<0.0001, One-way
ANOVA with Dunnet’s square post-hoc) (Figure 8D).
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Figure 7. MG132 treatment did not affect HERC5 mediated restriction
(A) 293T cells were co-transfected with empty vector or HERC5 and EGFP-VP40. 20μM
of 26S proteasome inhibitor MG132 was added to cells 32 hours after transfection and left
to treat cells for 16 hours. GFP-VP40 levels in VLPs released into supernatant (A) and cell
lysate (B) were analyzed by Western blot using anti-GFP and anti-β-actin as a loading
control, and quantified densitometrically (normalized to actin). (C) Representative
Western blot of three independent trials. ***, P<0.0005. **, P<0.005. Student’s paired t
test.
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Figure 8. HERC5 restricts VP40 mRNA
(A) HERC5 reduces intracellular VP40 mRNAs. 293T cells were co-transfected with
either empty vector (control) or HERC5 at a 10:1 ratio. 48 hours after transfection mRNA
was isolated and quantified using qRT-PCR. N=4. (B) HERC5 knockdown rescues VP40
mRNA. 293T cells were co-transfected with ControlsiRNA or HERC5siRNA and FLAGVP40. Forty-eight hours after transfection, cellular mRNA was isolated and quantified
using qRT-PCR. N=3. (C) HERC5 reduces VP40 independent of expression vector
backbone. 293T cells were co-transfected with either empty vector and one of VP40EGFP or VP40-pFLAG (Control), or HERC5 and one of VP40-EGFP or VP40-pFLAG.
GFP was used as a negative control. Forty-eight hours after transfection mRNA was
isolated and quantified using qRT-PCR. N=3. (D) HERC5 reduces intracellular EBOV
mRNA of other EBOV proteins. 293T cells were co-transfected with either empty vector
and one of VP40, VP30, VP35, L, NP or GP (Control), or with HERC5 and one of the
aforementioned proteins. Forty-eight hours after transfection, cellular mRNA was
isolated and quantified using qRT-PCR. N=3. *** P<0.001, **P<0.01, *P<0.05. Paired
T-test for A-B, one way ANOVA with post-hoc Dunnet’s square for C-D.
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3.4 The RLD domain of HERC5 is necessary and sufficient to cause restriction
To assess HERC5’s ability to reduce VP40 mRNA levels and corresponding
protein and VLP production, we utilized an assay involving HERC5 mutants to determine
which domain is responsible for HERC5-mediated restriction of VP40. 293T cells were
co-transfected with FLAG-VP40 and either empty vector (control), wild- type HERC5 or
a HERC5 mutant lacking one of the three HERC5 domains. Two other mutants, HERC5C994A and a HERC5 mutant only containing the RLD domain (HERC5-RLD-only) were
also used. The HERC5-C994 residue is the active site for E3 ligase activity, and is known
to be involved in HERC5-mediated restriction of HIV-1, influenza and HPV 16
pseudoviruses. E3 ligase activity is ablated by the C994A mutation 63,67,78.
Cells transfected with HERC5-ΔRLD showed a near complete rescue of
intracellular VP40 protein as analyzed by Western blot, compared to the 1.92-fold
reduction mediated by wild-type HERC5 (Figure 9A-B)(P<0.001, one-way ANOVA with
the HERC5-ΔRLD mutant (Figure 9A-B)(P<0.001, one-way ANOVA with post-hoc
Dunnet’s square). This corresponded with a rescue in VP40 VLP release; an 8.17-fold
reduction in VP40 VLPs mediated by HERC5 was reduced to a 1.92 fold reduction with
the HERC5-ΔRLD mutant (Figure 9A&C) (P<0.001, one-way ANOVA with post-hoc
Dunnet’s square). The other domain mutants showed restriction similar to wild-type
HERC5, including HERC5-ΔHECT, HERC5-C994A and HERC5-ΔSpacer (Figure 9B).
Since VP40 was transfected in a FLAG backbone, the VP40 and HERC-RLD-only mutants
were too similar in size to be distinguished by Western blot analysis. Cells were instead
co-transfected with GFP-VP40 and either empty vector (control), HERC5 or HERC-RLDonly and analyzed via Western blot. HERC5-RLD-only was able to reduce VP40
intracellular protein and VLP release similar to wild-type HERC5 (Figure 9D-E) (P>0.05,
one-way ANOVA with post-hoc Dunnet’s square).
Similar findings suggesting that the RLD domain is both necessary and sufficient
for HERC5-mediated restriction were seen at the RNA level. qPCR analysis revealed an
8.14-fold reduction in VP40 mRNA in the presence of wild-type HERC5, as opposed to a
1.72-fold reduction in the presence of HERC5-ΔRLD (Figure 9F) (P<0.01, one-way

Fold change VP40 mRNA
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Figure 9. The RLD is necessary and sufficient for restriction of VP40.
(A) Representative Western blot of three trials. 293T cells were co-transfected with FLAGVP40 and empty vector, HERC5, HERC5-ΔRLD, HERC5-RLD-only, HERC5-ΔSpacer,
HERC5-ΔHECT or HERC5-C994A. 48 hours after transfection VP40 levels in the cell
lysate and VLPs released into the supernatant were analyzed by Western blot using antiFLAG and anti-GAPDH. (B) Intracellular HERC5 restriciton of VP40 protein was rescued
by HERC5-ΔRLD, (C) as was the release of VP40 VLPs into the supernatant. (D)
Representative Western blot of three trials. 293T cells were transfected with EGFP-VP40,
and empty vector, HERC5 or HERC5-RLD only and analyzed via Western blot using antiGFP and anti-GAPDH. Intracellular (E) and VLP release (F) of VP40 was similar between
the WT and RLD-only HERC5. (G) HERC5 mediated restriction of VP40 mRNA was
partially rescued by HERC5-ΔRLD, while HERC5-RLD-only mediated restriction similar
to WT HERC5. 293T cells were co-transfected with FLAG-VP40 and empty vector,
HERC5, HERC5-ΔRLD, HERC5-RLD-only, HERC5-ΔSpacer, HERC5-ΔHECT or
HERC5-C994A. 48 hours after transfection mRNA was isolated and qRT-PCR was used
to detect intracellular VP40 mRNA levels. N=3. *** P<0.001, **P<0.01, *P<0.05. One
way ANOVA with post-hoc Dunnet’s square. All data are representative of at least three
independent experiments (N).
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ANOVA with post-hoc Dunnet’s square). The other domain mutants (HERC5-ΔSpacer,
HERC5-ΔHECT and HERC5-C994A) did not show a significant rescue in VP40 mRNA
levels (Figure 9F). Agreeing with the notion that the RLD domain is necessary for HERC5mediated restriction, the RLD-only mutant mediated a reduction in VP40 mRNA similar
to wild-type HERC5 (Figure 9F) (a 10.77-fold decrease in VP40 mRNA)(P<0.01, one-way
ANOVA with post-hoc Dunnet’s square). This data also shows that the E3 ligase activity
of HERC5 is not required for restriction.
3.6 HERC5 does not affect nuclear export of VP40 mRNA
Since we eliminated VP40 protein degradation as a major player in HERC5’s
activity, we thought that mRNA was instead being affected. Although EBOV does not
enter the nucleus during its regular life cycle, our VP40 assay is plasmid based and
therefore enters the nucleus to be transcribed and translated. Since HERC5 is known to
inhibit mRNA nuclear export of HIV-1’s structural protein78, we tested if HERC5 induced
the nuclear accumulation of VP40 mRNA. We performed a cytoplasmic extraction of cells
co-transfected with VP40 and either empty vector or HERC5, and compared mRNA levels
to the whole cell extracts. VP40 mRNA levels were not significantly different between the
cytoplasmic extract and whole cell extract (P>0.05, one-way ANOVA with Dunnet’s
square post-hoc) (Figure 10). This indicates that HERC5 likely does not cause nuclear
accumulation of VP40 mRNA, however we cannot rule out the possibility of degradation
of accumulated mRNA. This is important in establishing the biological relevance of our
findings.
3.7 HERC5 is dependent on ZAP for restriction at the RNA level
To further elucidate the mechanism that HERC5 utilizes to reduce EBOV VP40
mRNA levels, we investigated the involvement of ZAP, a protein known to recruit RNA
degradation factors and has previously been shown to target EBOV proteins for
degradation50. We transfected 293T cells with FLAG-VP40 and either empty vector
(control), HERC5, ZAP or HERC5 and ZAP together, followed by qRT-PCR to examine
VP40 mRNA levels. We were able to show that ZAP reduces VP40 mRNA by 7.54-fold,
which was not significantly different from HERC5 (P < 0.001, One-way ANOVA with
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Figure 10. HERC5 does not affect nuclear export of VP40 mRNA
293T cells were co-transfected with VP40 and either empty vector or HERC5. mRNA was
isolated from cytoplasmic and whole cell extracts, and subjected to qRT-PCR 48 hours
after transfection to determine VP40 mRNA levels. N = 3 (independent trials). One-way
ANOVA with Bonferroni post-hoc.
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post-hoc Dunnet’s square) (Figure 11A). When co-transfected, HERC5 and ZAP trend
towards increased restriction, with a 9.55-fold reduction in VP40 mRNA levels (P < 0.001,
One-way ANOVA with post-hoc Dunnet’s square) (Figure 11A). To determine if HERC5
requires ZAP to restrict VP40, we used a shRNA targeting ZAP to deplete endogenous
levels of ZAP (knockdown efficiency shown in Appendix B). 293T cells which basally
express ZAP were co-transfected with either scrambledshRNA or ZAPshRNA. As a positive
control showing HERC5-mediated restriction of VP40, we transfected scrambledshRNA
expressing 293T cells with VP40 and either empty vector (control) or HERC5 after 48
hours. HERC5 transfected cells showed a 3.33-fold reduction in VP40 mRNA (P< 0.01,
student’s paired T test) (Figure 11B). Contrastingly, in ZAPshRNA expressing cells, HERC5
did not mediate VP40 restriction (P>0.05, student’s paired T test) (Figure 11C).
Conversely, we asked if ZAP requires HERC5 for restriction of VP40 mRNA. We
co-transfected 293T cells with either scrambledshRNA or HERC5shRNA, followed by VP40
and either empty vector or ZAP (HERC5 knockdown efficiency can be found in Appendix
B). ZAP was able to reduce VP40 mRNA 9.80-fold in scrambledshRNA expressing cells,
agreeing with the restriction seen in Figure 11A (P<0.0001, student’s paired T test)(Figure
11D). ZAP was also able to reduce VP40 mRNA 8.77-fold in the absence of HERC5
(HERC5shRNA expressing cells) (P<0.0001, student’s paired T test)(Figure 11E), indicating
that ZAP is able to restrict VP40 independent of HERC5 recruitment.
3.8 ZAP and HERC5 are interaction partners and require the RLD domain for
interaction
Given ZAP’s involvement in HERC5-mediated restriction of VP40 mRNA, we
asked whether HERC5 was recruiting ZAP to degrade viral RNA. To answer this question
we used confocal microscopy of HeLA cells. Cells were transfected with empty vector,
ZAP, HERC5, or ZAP and HERC5 and visualized using anti-ZAP and anti-pFLAG (Figure
12A). Interestingly, the mean flourescence intensity of ZAP was significantly increased in
the presence of HERC5 compared to ZAP alone (P<0.0001, student’s paired T test)(Figure
12B). Pearson’s correlation coefficient indicated that HERC5 and ZAP significantly
colocalized ( r = 0.458, P<0.0001, One-way ANOVA with post-hoc Dunnet’s square)
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Figure 11. HERC5 necessitates ZAP for restriction of VP40 mRNA
(A) HERC5 and ZAP mediate restriction of VP40 mRNA. Restriction increases (albeit not
significantly different from H5 or ZAP alone) when HERC5 and ZAP are combined. 293T
cells were transfected with VP40, and either an empty vector, HERC5, ZAP, or HERC5 +
ZAP. RNA was isolated after 48 hours and quantified using qRT-PCR. N=3. (B-C) 293T
cells were transfected with either ScramledshRNA or ZAPshRNA. 48 hours after knockdown
cells were co-transfected with VP40 and either empty vector or HERC5. mRNA was
isolated and qPCR was used to detect VP40 levels 48 hours post-transfection. N=3. (B)
HERC5-mediated restriction in ScrambledshRNA transfected cells. (C) HERC5 no longer
mediates potent restriction in ZAPshRNA expressing cells. (D-E) 293T cells were transfected
with either ScrambledshRNA or HERC5shRNA. 48 hours after transfection cells were cotransfected with VP40 and either empty vector or ZAP, and harvested for RNA isolation
and qPCR 48 hours later. (D) ZAP mediated restriction in ScrambledshRNA expressing cells
and in (E) HERC5shRNA expressing cells. **** P<0.0001, *** P<0.001, **P<0.01,
*P<0.05. One way ANOVA with post-hoc Dunnet’s square in A and student’s paired T
test in B-E. All data are representative of at least three independent experiments (N).

51

(Figure 12C). These data show that HERC5 may be upregulating ZAP expression, and
supports HERC5’s recruitment of ZAP to VP40 mRNA.
To investigate this further, we determined if HERC5 and ZAP were interaction
partners through co-immunoprecipitation. 293T cells were transfected with either empty
vector, wild-type HERC5 or one of the HERC5 mutants. 48 hours after transfection cells
were lysed under non-denaturing conditions and magnetic beads targeting FLAG tagged
HERC5 were used to pull down HERC5 and interaction partners. Precipitated proteins
were resolved using SDS-PAGE and subjected to Western blotting using anti-ZAP. ZAP
was co-immunoprecipitated in the presence of wild-type HERC5 and HERC-RLD-only,
but not in the presence of HERC5-ΔRLD (Figure 12D).
3.9 HERC5’s specificity for VP40 is not related to CG dinucleotide content
Recent research has shown that high CG dinucleotide content within viral genomes
increases ZAP antiviral activity52. We thought that ZAP may be targeting VP40 mRNA for
degradation by recognizing a high CG dinucleotide content within its RNA. We used a 200
bp sliding window to analyze CG dinucleotide content across the EBOV genome
(sequences found in Appendix A). There was no significant difference between the CG
dinucleotide content of each viral mRNA (P>0.05, One-way ANOVA with Bonferroni
post-hoc) (Figure 13).
As a control we also analyzed HIV-1 coding sequences for CG dinucleotide
content. This virus is known to exhibit CG dinucleotide suppression to avoid recognition
by ZAP52. Consistent with this study, mRNA within the EBOV genome contained
significantly higher levels of CG dinucleotides than HIV-1 (P<0.01, One-way ANOVA
with Bonferroni post-hoc test) (Figure 13).
3.10 Ebola GP can antagonize HERC5 mediated restriction of VP40 protein and
mRNA
EBOV is able to mount a potent suppression towards the Type I IFN response
during infection, lending support towards the notion that EBOV harbours mechanisms to
antagonize IFN induced HERC574,87,88,93,95. We tested a panel of EBOV proteins for
potential antagonism of HERC5-mediated restriction of EBOV VP40. 293T cells were
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Figure 12. HERC5 interacts with ZAP through the RLD domain
(A) Representative confocal micrographs of HERC5 and ZAP co-expression. HeLa cells
were co-transfected with either empty vector, ZAP, HERC5, or ZAP and HERC5 and
probed with anti-FLAG and anti-ZAP. Scale bars = 10 µm. (B) Mean fluorescence intensity
of ZAP. Cells were outlined with the nucleus excluded, and analyzed for mean fluorescence
intensity of the region of interest (ROI). (C) Pearson’s correlation coefficient showed
significant colocalization between ZAP and HERC5. (D) 293T cells were transfected with
either empty vector, HERC5, HERC5-ΔRLD, HERC5-RLD-only, HERC5-ΔSpacer, or
HERC5-ΔHECT. HERC5 was immunoprecipitated under non-denaturing conditions using
anti-FLAG magnetic beads. Precipitated proteins were resolved using SDS-PAGE and
subjected to Western blotting using anti-ZAP. 30% of the input lysate from each condition
was subjected to Western blotting using anti-ZAP and anti-GAPDH on the same blot. ZAP
was pulled down in the presence of HERC and HERC5-RLD-only, but not HERC5-ΔRLD.
*** P<0.001, **P<0.01, *P<0.05. Student’s paired T test in C. One-way ANOVA with
post-hoc Dunnet’s square in D.
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Figure 13. CG dinucleotide content within the EBOV genome
A 200 base-pair sliding window was used to count CG dinucleotide content within the
EBOV (19kb) and HIV-1 genome (9kb) (nucleotide sequences shown in Appendix A). A
model of the EBOV genome is shown along the top to indicate the regions of each viral
protein. CG dinucleotide content for each EBOV protein sequence is significantly higher
than HIV-1 (P<0.01, One-way ANOVA with Bonferroni post-hoc). No significant
differences in CG dinucleotide content between EBOV protein sequences.
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transfected with either empty vector or HERC5, plus VP40 and one of EBOV VP30, VP35,
NP, L or GP. 48 hours after transfection, cells were harvested and analyzed using western
blot or qPCR. The presence of VP35, VP30 or NP showed similar restriction of VP40
compared to cells transfected with HERC5 and VP40 alone (Figure 14A-B). Interestingly,
the presence of L protein or GP showed a rescue in intracellular VP40 protein and mRNA
that was not significantly different from control (P>0.05, student’s T test) (Figure 14A-B).
Additionally, HERC5 was no longer able to mediate restriction of VLPs being released
into the supernatant in the presence of GP (Figure 14A).
To determine if HERC5 levels were altered in the presence of GP, we measured
HERC5 protein levels via quantitative Western blotting. HERC5 protein levels were not
significantly altered when co-transfected with VP40 and any of the EBOV proteins (Figure
14C).
3.11 GP antagonism is specific to filoviral GPs
Since EBOV GP was able to potently antagonize HERC5 activity at the protein and
RNA level, we decided to test whether this antagonism was specific to EBOV GP or if
other viral envelope GPs are able to similarly antagonize HERC5. We transfected 293T
cells with VP40, either empty vector or HERC5 and one of either EBOV GP, Marburg
Virus GP or an irrelevant envelope protein – Vesicular Stomatitis Virus G (VSV-G). We
examined intracellular VP40 protein levels, VP40 VLPs released into the supernatant and
VP40 mRNA. Interestingly, the presence of VSV G did not affect HERC5’s ability to
restrict intracellular VP40 protein (P<0.01, One-way ANOVA with Dunnett’s square posthoc) (Figure 15A-B & C-D respectively). HERC5 was also able to significantly restrict
VP40 mRNA in the presence of VSV G (P< 0.01, One-way ANOVA with Dunnett’s square
post-hoc) (Figure 15E). In contrast, HERC5 expressing cells in the presence of EBOV GP
or Marburg GP showed VP40 protein and mRNA levels similar to control (Figure 15A-E).
This is interesting since EBOV GP only shares 34.40% identity with Marburg GP when
the protein sequences were aligned using Clustal Omega (Figure 15F).
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Figure 14. EBOV L and GP antagonize HERC5 mediated restriction of VP40
293T cells were co-transfected with VP40, either empty vector or HERC5 and one plasmid
containing an EBOV protein. (A) VP40 levels in cell lysate and VLPs released into
supernatant were analyzed by Western blot using anti-GFP and anti-GAPDH as a loading
control, and quantified densitometrically (normalized to GAPDH). N=6. Includes
representative Western blots analyzed using anti-GFP, and anti-GAPDH. (B) VP40 mRNA
levels were quantified using qRT-PCR after co-transfection as explained previously. N=3.
(C) HERC5 protein levels remained consistent in the presence of VP40 and each of the
other EBOV proteins. 293T cells were co-transfected with VP40, HERC5 and one of the
EBOV proteins followed by densitometric analysis.*** P<0.001, **P<0.01, *P<0.05.
Student’s paired T test in A and one way ANOVA with post-hoc Dunnet’s square in B &
C. All data are representative of at least three independent experiments (N).
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Figure 15. HERC5 antagonism is specific to filoviral GPs.
293T cells were co-transfected with VP40, either empty vector or HERC5 and either
EBOV GP, Marburg GP or VSV G. (A) VP40 levels in cell lysate were analyzed by
Western blot using anti-FLAG and anti-GAPDH as a loading control, and quantified
densitometrically (normalized to GAPDH). N=3. (B) Shows representative Western blots
analyzed using anti-FLAG, and anti-GAPDH. (C) Densitometric analysis of VP40 VLP
levels in supernatant. (D) Representative Western blots analyzed using anti-FLAG. Note
that these samples were run on separate Western blots, therefore blots shown in B and D
are a combination of 3 different blots. (E) VP40 mRNA levels were quantified using qRTPCR after co-transfection as explained previously. N=3. (F) Clustal Omega multiple
alignment of VSVG, EBOV GP and Marburg GP protein sequences. EBOV GP shares
34.40% identity with Marburg GP and 16.50% with VSV G. GenBank Accession EBOV
GP: AAG40168.1; Marburg GP: APQ46224.1, VSV G: AAA48389.1. ***P<0.001,
**P<0.01, *P<0.05. One way ANOVA with post-hoc Dunnet’s square. All data are
representative of at least three independent experiments (N).
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CHAPTER 4 – DISCUSSION
We have identified HERC5 as a novel IFN-induced protein that is able to restrict
EBOV VP40 intracellular mRNA and restrict the release of assembled VLPs from the
plasma membrane. The RLD domain located at the amino terminus of HERC5 was
necessary and sufficient for HERC5-mediated restriction of EBOV VP40, and mediated an
interaction between HERC5 and ZAP. ZAP is a protein involved in RNA degradation that
we have demonstrated to be required for HERC5 restriction of VP40 mRNA. We also
showed that GP antagonizes HERC5-mediated restriction of VP40 mRNA, protein and
VLP release.
The mammalian Type I IFN response is strongly upregulated during EBOV
infection, however few IFN-induced proteins have been identified which act to inhibit
EBOV replication35,72,75. The identification of HERC5 as an inhibitor of EBOV VP40 VLP
production deduces a novel innate defense mechanism against EBOV. Data presented by
Johnson et al. (2016) and Noda et al. (2002) show the formation of VP40 VLPs through
confocal and transmission electron microscopy that are consistent with the VLPs produced
in our assay25,103. The particles in our transmission electron micrographs were ~100nm in
diameter, agreeing with the aforementioned studies and with the size of wild-type virus
(80nm)25,103. Most of our particles were spherical in shape, which are likely cross sections
of filamentous particles. These particles also appeared to be budding vertically from the
cell; vertical particles are known to be less infectious, which agrees with the nature of our
assay – it does not contain the nucleocapsid hypothesized to be responsible for horizontal
budding22. Our confocal micrographs were also in agreement with prior literature showing
GFP-VP40 bodies along the plasma membrane indicative of budding19,74,103. However, this
was only seen with the VP40 construct that has the GFP tag at the amino-terminus. The
absence of immunoreactivity in Western blots shown in Figure 5B and diffuse fluorescence
throughout the cytoplasm in the confocal micrographs of carboxyl-tagged GFP-VP40
suggests that this construct fails to bud and resembles what is seen with truncated VP4019.
Hence, GFP likely interferes with the function of the C-terminus of VP40, including
electrostatic and hydrophobic properties inducing plasma membrane attachment and eventual
VLP formation. Membrane attachment induces negative curvature changes in the plasma
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membrane consistent with VP40 pushing the inner leaflet of the plasma membrane out of the
cell to form a VLP19. Despite the inefficient formation of VLPs in cells expressing GFP at the
carboxy terminus of VP40, cells expressing VP40 with GFP at the amino terminus represented
an efficient model of VLP release. We have therefore demonstrated a morphologically and

biologically relevant assay that depicts HERC5-mediated restriction of VP40. It should
also be noted that our studies were largely performed in 293T cells, which are human
kidney fibroblasts – a cell type known to be infected during the onset of EBOV infection5.
HERC5 showed its largest capacity to restrict VP40 mRNA, though other EBOV
mRNAs were also reduced. It is known that HERC5 is recruited to polyribosomes
concurrent with translation of new proteins, though it remains unclear why VP40 may be
targeted more favorably than other EBOV RNAs68. It is possible that the RLD domain is
involved in the recruitment of HERC5 to particular viral mRNAs, as this domain has been
shown to be important for co-localization of HERC5 and polyribosomes64,68. The
polyribosome is a likely site for HERC5 interaction with viral mRNA, as proteins are being
newly synthesized from mRNA64,68. This agrees with our findings that the RLD domain is
both necessary and sufficient for HERC5-mediated restriction of EBOV VP40 mRNA and
protein. We have revealed a novel antiviral mechanism for HERC5, which is independent
of E3 ligase activity performed by the active site (Cys994) within the HECT domain 64,104.
HERC5’s E3 ligase activity has been shown to block the function of many viral proteins
including HIV-1 Gag and influenza A NS1, and to interfere with the infectivity of HPV
pseudovirses64,67,79. It is therefore interesting to identify a novel mechanism not only
independent of E3 ligase activity, but independent of any other known function of HERC5.
Woods et al. (2011) were able to show that the RLD domain blocks the nuclear export of
unspliced HIV-1 RNA, but this exhausts the known functions of the RLD domain within
HERC578. Given that the amount of mRNA within the cytoplasmic and whole cell extracts
did not significantly differ (Figure 10), we eliminated blocking of VP40 nuclear export as
a possible HERC5 mediated mechanism for EBOV restriction. This lends support to the
idea that HERC5 plays a role in the hosts innate defense against EBOV, as EBOV mRNA
is translated in the cytoplasm and does not enter the nucleus. HERC5 blocking nuclear
export of our plasmid-based VP40 construct would be biologically irrelevant; eliminating
this possibility was important in supporting a biologically relevant mechanism for VP40

63

restriction. Delving further into the underlying mechanisms of HERC5 and the spectrum
of pathogens that it targets is especially important given that HERC5 is evolutionarily
conserved among mammalian vertebrate hosts78. This research is therefore relevant to
various hosts outside of humans.
We showed that HERC5’s mechanism does not involve targeting VP40 protein to
the 26S proteasome, though increased VP40 levels may be seen with MG132 treatment
due to normal protein turnover105. MG132 acts by covalently binding the active site of the
beta subunits in the 20S proteasome, blocking the proteolytic activity of the 26S
proteasome complex106. Since this complex is the major degradation site for proteins in
eukaryotic cells106, an increase in total protein would be expected when it is inhibited.
Importantly, HERC5 was still able to restrict VP40 protein when cells were treated with
MG132. Our findings differ from the mechanistic action of other HERC family members,
namely HERC3. HERC3 directly interacts with the proteasome to lead to degradation of
RelA37107. HERC5 on the other hand, reduces VP40 protein levels both without and with
proteasome inhibition, suggesting that HERC5 does not interact with the 26S proteasome
complex and that protein degradation is not involved in HERC5’s activity towards EBOV.
This study instead identified a mechanism of HERC5-mediated restriction
requiring ZAP activity. ZAP is known to recognize ZREs within viral mRNA, and cause
downstream RNA degradation by the RNA processing exosome46. ZAP has also been
shown to act synergistically with other Type I IFN induced proteins to mount an antiviral
response against alphaviruses, making plausible its involvement and direct interaction with
HERC5 to reduce EBOV VP40 mRNA54. In fact, a study by Muller et al. (2007) has shown
that ZAP acts to decrease mRNA levels of EBOV proteins including VP40, although the
RNA dependent RNA polymerase (L protein) was affected the most50. Given that we have
identified ZAP to be involved in HERC5-mediated restriction of VP40, it is logical that the
reduction in VP40 is amplified greater than that seen by Muller et al. (2007) when HERC5
is overexpressed50.
We were also able to show that ZAP restricts VP40 independent of HERC5. When
ZAP was overexpressed alone, VP40 mRNA levels were reduced similar to that seen in
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the overexpression of HERC5. This suggests that HERC5 is not required for ZAP-mediated
restriction at highly elevated levels of ZAP expression, although HERC5 and ZAP may
have an additive effect when overexpressed together. This is supported by knockdown
assays of HERC5, in which ZAP is still able to cause a reduction in VP40 mRNA when
HERC5 is absent. We hypothesize that this is due to the nature of HERC5 acting upstream
from ZAP; HERC5 activates or recruits ZAP to degrade VP40. ZAP activity is therefore
enhanced in the presence of HERC5, but HERC5 is not absolutely required for degradation.
Co-immunoprecipitation assays determined that there is an interaction between
HERC5 and ZAP that may promote activity towards VP40. Agreeing with our previous
findings identifying the RLD domain as the active domain, the RLD mediated an
interaction with ZAP. Given the RLD’s role in mediating HERC5’s recruitment to the
polyribosome, we speculate that the RLD is recruiting ZAP to the complex for viral mRNA
degradation. This was further investigated through confocal fluorescence microscopy, in
which there was a strong colocalization between HERC5 and ZAP. Additionally, ZAP’s
intensity was significantly higher in the presence of HERC5. Together, these findings
suggest that HERC5 and ZAP form a complex, in which there could be a direct interaction
between the two, or indirect interaction where HERC5 may perform ISGylation. Although
ISGylation was proven to not to be required for restriction, close proximity of the two
proteins may incidentally ISGylate and stabilize ZAP. This would explain the increase in
intensity of ZAP in the presence of HERC5, especially since ZAP is already known to be
stabilized by an ISG15-like molecule, ubiquitin, through TRIM2556,57. Stabilization by
TRIM25 has been shown to be important in ZAP’s restriction of Sindbis virus56,57.
Furthermore, HERC5 is known to use ISGylation to stabilize other IFN-induced proteins
such as IRF385.
Identification of ZAP as an interaction partner in HERC5-mediated restriction led
us to wonder whether ZAP is also responsible for HERC5’s specificity towards VP40
mRNA. As previously mentioned, HERC5 can restrict all EBOV proteins, but VP40 was
reduced to the highest extent. Although ZAP does not have a known target sequence, it is
known to target and bind regions of foreign RNA that are rich in CG dinucleotides52. After
investigation of the CG dinucleotide content of each viral protein, we concluded that there
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was not a significantly higher CG dinucleotide content within VP40 compared to the other
EBOV mRNAs. However, the entire EBOV genome contained a significantly higher
relative amount of CG dinucleotides compared to HIV-1. This agrees with previous
findings showing CG dinucleotide suppression in HIV-1 and gives one explanation as to
how HERC5 and ZAP coordinate to target EBOV but not HIV-1 RNA52.
It is important to note that although we have identified ZAP as a downstream
partner involved in HERC5 mediated restriction, there are likely other proteins or
mechanisms at play given the complexity of the IFN response. Specifically, we believe
there is a second blockade mediated by HERC5 in which fully formed VLPs are trapped at
the plasma membrane. This is supported by our TEM images displaying VLPs beneath the
plasma membrane, and confocal images showing GFP-VP40 VLPs localized along the
membrane. A secondary mechanism is also supported by our Western blots. What we have
found in this report is that, contingent on the RLD domain, HERC5 initiates mRNA
degradation through an interaction with ZAP. A downstream reduction in VP40 protein
and subsequent VLP release is thus caused. When the RLD is deleted, the intracellular
VP40 protein is fully rescued, but VLPs being released into the supernatant are still
modestly reduced – suggesting a mechanism exists between the production of protein and
release of VLPs that is independent of the RLD domain. HERC5 has been shown to prevent
an early stage of viral assembly in HIV-1, where it prevents the release of VLPs along the
plasma membrane64. Although this would not be the primary mechanism used by HERC5
towards EBOV, a mechanism similar to that seen in HIV-1 could contribute to the overall
reduction in VP40 VLP release at the plasma membrane.
In HIV-1, ISGylation acts to interfere with an early stage of assembly of viral
particles64. In this study we have identified a mechanism of restriction that is independent
of E3 ligase activity, which may seem contrary to our proposed secondary mechanism.
However, we hypothesize that the primary mechanism involving ZAP saturates HERC5’s
restriction capabilities when the RLD domain is present. This is supported by our
transmission electron micrographs in which very few fully formed particles were
measured; the minimal particles that were assembled could then be restricted by the
secondary mechanism. This secondary mechanism may therefore only contribute
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significantly when the RLD domain is deleted. It is thus important for future experiments
to study whether HERC5 is able to mediate restriction in a HERC5-ΔRLD-ΔHECT or
HERC5-ΔRLD-C994A mutant form.
EBOV’s potent ability to suppress the Type I IFN response is consistent with our
finding that EBOV GP and L protein antagonize HERC5-mediated restriction of VP40
mRNA and protein. GP has already been shown to be involved in the suppression of the
Type I IFN response by interrupting the antiviral activity of the IFN-induced protein
tetherin75. We have now identified a second mechanism by which EBOV GP defends itself
from the host immune response. Although we began investigating the mechanism by which
GP may act to antagonize HERC5, it remains elusive how this protein suppresses HERC5
function. It is likely that GP interrupts the restriction complex, given its ability to fully
rescue VP40 mRNA, protein and VLP release. Since GP is a transmembrane protein, it is
possible that GP also functions at the plasma membrane, as it is speculated to do during
antagonism of tetherin. GP antagonism may therefore be involved in antagonizing
HERC5’s ability to trap particles at the plasma membrane – a mechanism we have yet to
investigate. Furthermore, our study showed that this antagonism is specifically mediated
by filoviral GPs; our research may elude to a novel mechanism whereby filoviral GPs target
the IFN response and HERC5 in particular.
Interestingly, we have identified a second antagonist, L protein, which prevents
HERC5’s activity towards VP40 mRNA and modestly towards intracellular protein, but
fails to antagonize HERC5’s restriction of VP40 VLP release into the supernatant. It is
possible therefore that L protein antagonizes HERC5-mediated degradation of VP40
mRNA, but is unable to prevent the restriction of VLPs at the plasma membrane. Similar
to GP, this mechanism remains to be elucidated.
4.1 Limitations of the study
As aforementioned, we were unable to clone VP24 into a mammalian expression
vector. We were hence unable to test whether HERC5 reduces VP24 mRNA levels as it
does the other EBOV proteins. We were also unable to test potential antagonism mediated
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by VP24 towards HERC5. Given VP24’s known ability to counter the IFN response, it
may potentially also target HERC598.
The main limitation of this study was the absence of a more biologically relevant
system, involving all of the Ebola proteins in an infectious pseudovirus system.
Investigating HERC5’s role in an infectious system is important in establishing the
relevance of HERC5 in an actual EBOV infection. This will allow us to determine whether
HERC5 plays a role in multi-round infections and to further study EBOV’s antagonism of
HERC5 in the presence of all of the viral proteins. Using a biologically relevant system
allows for a more thorough understanding of the virus-host interplay and how HERC5 is
involved in the human defense against EBOV infection as a whole. This data is crucial
moving forward and may lead to the study of HERC5 within a fully replication competent
system modeling wild type infection.
4.2 Future directions
We aim to further elucidate the HERC5-ZAP pathway using mass spectrometry to
examine other potential interaction partners such as the RNA processing exosome or
PARN46,109. These are downstream mRNA degradation factors known to be recruited by
ZAP and would further confirm this pathway. We also plan to perform the coimmunoprecipitation studies in the presence of RNAse, to determine if viral VP40 mRNA
is required for the HERC5-ZAP interaction to take place. Furthermore, a sequencing
technology called CLIP-seq will allow us to identify binding sites for ZAP or HERC5
within viral mRNA. In brief, CLIP-seq couples proteins to their RNA targets, degrades
RNA outside of the binding region and sequences this region. Although analysis of the
EBOV genome showed that CG dinucleotide content is an unlikely cause for VP40
targeting, a specific target sequence may still be responsible. This would also potentially
reveal a sequence specific target region for ZAP or ZREs, which has not been identified
before.
Future directions also include exploring other possible mechanisms used by
HERC5 to restrict VP40. Specifically, we plan to utilize TEM and confocal microscopy to
study viral restriction that was seen at the plasma membrane but was not further
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investigated in this study. Using our domain mutants will be important in determining
which domain is responsible for virus trapping at the plasma membrane, and will be our
first step in elucidating the potential for this secondary mechanism. Visualizing the effect
of the GP antagonist on VLP release will also be important in beginning to study its method
of antagonism.
Most importantly, we aim to test HERC5’s effect on the release of infectious EBOV
pseudovirions using the system outlined by Mühlberger et al. (2017)110. This a transcription
and replication competent VLP system (trVLP) and is based on a tetracistronic
minigenome that encodes a luciferase reporter, as well as VP40, VP24, and GP. Coexpression of this minigenome together with NP, VP35, VP30, and L drive genome
replication and transcription, synthesis of the minigenome-encoded proteins, and formation
of trVLPs. These trVLPs can incorporate minigenomes and infect target cells for multiple
passages. Propagation of these trVLPs can be quantified over time (every three days) by
measuring the luciferase reporter activity within cells at different passages. This system
can be used within a wide range of cell types, can be utilized in a Biosafety Level 2
laboratory, and has been identified as a tool for antiviral drug screens for EBOV
infection110. This system will be important in our study of HERC5’s restriction capabilities
during EBOV infection and research into the virus-host interplay by looking at the effect
of HERC5 on multi-round infections. Additionally, we have initiated a collaboration with
Dr. Gary Kobinger, the developer of ZMapp and chief of special pathogens at the Public
Health Agency of Canada’s (PHAC) Biosafety Level 4 microbiology laboratory in
Winnipeg, to study HERC5 in wild-type EBOV infection. Together these studies may lead
to the long-term goal of studying novel small molecule drugs that exploit HERC5’s
restriction capabilities while preventing viral antagonism towards the IFN response.
4.3 Conclusions
EBOV is one of the most virulent pathogens to infect humans. EBOV’s extreme
pathogenesis can be largely attributed to its ability to globally and selectively suppress the
Type I IFN response, yet the effect that the IFN response plays in defending the host during
infection remains largely uncharacterized. Gaining a broad sense of the virus-host interplay
during infection, especially with respect to the Type I IFN response, plays a large part in
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understanding EBOV disease. Filling the gaps in knowledge regarding the interaction
between EBOV and the innate immune response is critical in building a strong foundation
of knowledge in EBOV pathology, immunological research, and the development of future
therapeutic strategies.
Overall, by showing that the IFN-induced protein HERC5 targets EBOV VP40
mRNA, we have identified a novel antiviral mechanism targeting EBOV. Moreover, the
ability of HERC5 to deplete viral RNA via its RLD domain and ZAP identifies a novel E3
ligase-independent antiviral mechanism for HERC5. Importantly, we have identified
EBOV GP as an antagonist towards HERC5 activity – identifying a novel point at which
EBOV can suppress the innate immune response and mitigate the host’s antiviral defense.
Moving forward, this information not only furthers knowledge regarding EBOV and the
human immune response towards it, but is also translatable to therapeutic strategies that
can mimic the effects of HERC5 while inhibiting antagonistic activity mediated by Ebola
virus GP.
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Appendices
Appendix A. Ebola protein sequences
Gene: Sequence*
VP40:ATGtacgatgttccagattacgctgctgctAGGCGGGTTATATTGCCTACTGCTCCTCCTGAATATATGGAGGCCATA
TACCCTGTCAGGTCAAATTCAACAATTGCTAGAGGTGGCAACAGCAATACAGGCTTCCTGACACCGGAGT
CAGTCAATGGGGACACTCCATCGAATCCACTCAGGCCAATTGCCGATGACACCATCGACCATGCCAGCCA
CACACCAGGCAGTGTGTCATCAGCATTCATCCTTGAAGCTATGGTGAATGTCATATCGGGCCCCAAAGTGC
TAATGAAGCAAATTCCAATTTGGCTTCCTCTAGGTGTCGCTGATCAAAAGACCTACAGCTTTGACTCAACT
ACGGCCGCCATCATGCTTGCTTCATACACTATCACCCATTTCGGCAAGGCAACCAATCCACTTGTCAGAGT
CAATCGGCTGGGTCCTGGAATCCCGGATCATCCCCTCAGGCTCCTGCGAATTGGAAACCAGGCTTTCCTCC
AGGAGTTCGTTCTTCCGCCAGTCCAACTACCCCAGTATTTCACCTTTGATTTGACAGCACTCAAACTGATC
ACCCAACCACTGCCTGCTGCAACATGGACCGATGACACTCCAACAGGATCAAATGGAGCGTTGCGTCCAG
GAATTTCATTTCATCCAAAACTTCGCCCCATTCTTTTACCCAACAAAAGTGGGAAGAAGGGGAACAGTGCC
GATCTAACATCTCCGGAGAAAATCCAAGCAATAATGACTTCACTCCAGGACTTTAAGATCGTTCCAATTGA
TCCAACCAAAAATATCATGGGAATCGAAGTGCCAGAAACTCTGGTCCACAAGCTGACCGGTAAGAAGGTG
ACTTCTAAAAATGGACAACCAATCATCCCTGTTCTTTTGCCAAAGTACATTGGGTTGGACCCGGTGGCTCC
AGGAGACCTCACCATGGTAATCACACAGGATTGTGACACGTGTCATTCTCCTGCAAGTCTTCCAGCTGTGA
TTGAGAAGTAA
VP35:ATGACAACTAGAACAAAGGGCAGGGGCCATACTGCGGCCACGACTCAAAACGACAGAATGCCAGG
CCCTGAGCTTTCGGGCTGGATCTCTGAGCAGCTAATGACCGGAAGAATTCCTGTAAGCGACATCTTCTGTG
ATATTGAGAACAATCCAGGATTATGCTACGCATCCCAAATGCAACAAACGAAGCCAAACCCGAAGACGCG
CAACAGTCAAACCCAAACGGACCCAATTTGCAATCATAGTTTTGAGGAGGTAGTACAAACATTGGCTTCA
TTGGCTACTGTTGTGCAACAACAAACCATCGCATCAGAATCATTAGAACAACGCATTACGAGTCTTGAGA
ATGGTCTAAAGCCAGTTTATGATATGGCAAAAACAATCTCCTCATTGAACAGGGTTTGTGCTGAGATGGTT
GCAAAATATGATCTTCTGGTGATGACAACCGGTCGGGCAACAGCAACCGCTGCGGCAACTGAGGCTTATT
GGGCCGAACATGGTCAACCACCACCTGGACCATCACTTTATGAAGAAAGTGCGATTCGGGGTAAGATTGA
ATCTAGAGATGAGACCGTCCCTCAAAGTGTTAGGGAGGCATTCAACAATCTAAACAGTACCACTTCACTA
ACTGAGGAAAATTTTGGGAAACCTGACATTTCGGCAAAGGATTTGAGAAACATTATGTATGATCACTTGC
CTGGTTTTGGAACTGCTTTCCACCAATTAGTACAAGTGATTTGTAAATTGGGAAAAGATAGCAACTCATTG
GACATCATTCATGCTGAGTTCCAGGCCAGCCTGGCTGAAGGAGACTCTCCTCAATGTGCCCTAATTCAAAT
TACAAAAAGAGTTCCAATCTTCCAAGATGCTGCTCCACCTGTCATCCACATCCGCTCTCGAGGTGACATTC
CCCGAGCTTGCCAGAAAAGCTTGCGTCCAGTCCCACCATCGCCCAAGATTGATCGAGGTTGGGTATGTGTT
TTTCAGCTTCAAGATGGTAAAACACTTGGACTCAAAATTTGA
VP30:ATGGAAGCTTCATATGAGAGAGGACGCCCACGAGCTGCCAGACAGCATTCAAGGGATGGACACGAC
CACCATGTTCGAGCACGATCATCATCCAGAGAGAATTATCGAGGTGAGTACCGTCAATCAAGGAGCGCCT
CACAAGTGCGCGTTCCTACTGTATTTCATAAGAAGAGAGTTGAACCATTAACAGTTCCTCCAGCACCTAAA
GACATATGTCCGACCTTGAAAAAAGGATTTTTGTGTGACAGTAGTTTTTGCAAAAAAGATCACCAGTTGGA
GAGTTTAACTGATAGGGAATTACTCCTACTAATCGCCCGTAAGACTTGTGGATCAGTAGAACAACAATTA
AATATAACTGCACCCAAGGACTCGCGCTTAGCAAATCCAACGGCTGATGATTTCCAGCAAGAGGAAGGTC
CAAAAATTACCTTGTTGACACTGATCAAGACGGCAGAACACTGGGCGAGACAAGACATCAGAACCATAG
AGGATTCAAAATTAAGAGCATTGTTGACTCTATGTGCTGTGATGACGAGGAAATTCTCAAAATCCCAGCTG
AGTCTTTTATGTGAGACACACCTAAGGCGCGAGGGGCTTGGGCAAGATCAGGCAGAACCCGTTCTCGAAG
TATATCAACGATTACACAGTGATAAAGGAGGCAGTTTTGAAGCTGCACTATGGCAACAATGGGACCGACA
ATCCCTAATTATGTTTATCACTGCATTCTTGAATATTGCTCTCCAGTTACCGTGTGAAAGTTCTGCTGTCGT
TGTTTCAGGGTTAAGAACATTGGTTCCTCAATCAGATAATGAGGAAGCTTCAACCAACCCGGGGACATGC
TCATGGTCTGATGAGGGTACCCCTTAA
VP24:ATGtacgatgttccagattacgctgctgctGCTAAAGCTACGGGACGATACAATCTAATATCGCCCAAAAAGGACCT
GGAGAAAGGGGTTGTCTTAAGCGACCTCTGTAACTTCTTAGTTAGCCAAACTATTCAGGGGTGGAAGGTTT
ATTGGGCTGGTATTGAGTTTGATGTGACTCACAAAGGAATGGCCCTATTGCATAGACTGAAAACTAATGA
CTTTGCCCCTGCATGGTCAATGACAAGGAATCTCTTTCCTCATTTATTTCAAAATCCGAATTCCACAATTGA
ATCACCGCTGTGGGCATTGAGAGTCATCCTTGCAGCAGGGATACAGGACCAGCTGATTGACCAGTCTTTG
ATTGAACCCTTAGCAGGAGCCCTTGGTCTGATCTCTGATTGGCTGCTAACAACCAACACTAACCATTTCAA
CATGCGAACACAACGTGTCAAGGAACAATTGAGCCTAAAAATGCTGTCGTTGATTCGATCCAATATTCTCA
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AGTTTATTAACAAATTGGATGCTCTACATGTCGTGAACTACAACGGATTGTTGAGCAGTATTGAAATTGGA
ACTCAAAATCATACAATCATCATAACTCGAACTAACATGGGTTTTCTGGTGGAGCTCCAAGAACCCGACA
AATCGGCAATGAACCGCATGAAGCCTGGGCCGGCGAAATTTTCCCTCCTTCATGAGTCCACACTGAAAGC
ATTTACACAAGGATCCTCGACACGAATGCAAAGTTTGATTCTTGAATTTAATAGCTCTCTTGCTATCTAA
NP:ATGGATTCTCGTCCTCAGAAAATCTGGATGGCGCCGAGTCTCACTGAATCTGACATGGATTACCACAA
GATCTTGACAGCAGGTCTGTCCGTTCAACAGGGGATTGTTCGGCAAAGAGTCATCCCAGTGTATCAAGTA
AACAATCTTGAAGAAATTTGCCAACTTATCATACAGGCCTTTGAAGCAGGTGTTGATTTTCAAGAGAGTGC
GGACAGTTTCCTTCTCATGCTTTGTCTTCATCATGCGTACCAGGGAGATTACAAACTTTTCTTGGAAAGTGG
CGCAGTCAAGTATTTGGAAGGGCACGGGTTCCGTTTTGAAGTCAAGAAGCGTGATGGAGTGAAGCGCCTT
GAGGAATTGCTGCCAGCAGTATCTAGTGGAAAAAACATTAAGAGAACACTTGCTGCCATGCCGGAAGAGG
AGACAACTGAAGCTAATGCCGGTCAGTTTCTCTCCTTTGCAAGTCTATTCCTTCCGAAATTGGTAGTAGGA
GAAAAGGCTTGCCTTGAGAAGGTTCAAAGGCAAATTCAAGTACATGCAGAGCAAGGACTGATACAATATC
CAACAGCTTGGCAATCAGTAGGACACATGATGGTGATTTTCCGTTTGATGCGAACAAATTTTCTGATCAAA
TTTCTCCTAATACACCAAGGGATGCACATGGTTGCCGGGCATGATGCCAACGATGCTGTGATTTCAAATTC
AGTGGCTCAAGCTCGTTTTTCAGGCTTATTGATTGTCAAAACAGTACTTGATCATATCCTACAAAAGACAG
AACGAGGAGTTCGTCTCCATCCTCTTGCAAGGACCGCCAAGGTAAAAAATGAGGTGAACTCCTTTAAGGC
TGCACTCAGCTCCCTGGCCAAGCATGGAGAGTATGCTCCTTTCGCCCGACTTTTGAACCTTTCTGGAGTAA
ATAATCTTGAGCATGGTCTTTTCCCTCAACTATCGGCAATTGCACTCGGAGTCGCCACAGCACACGGGAGT
ACCCTCGCAGGAGTAAATGTTGGAGAACAGTATCAACAACTCAGAGAGGCTGCCACTGAGGCTGAGAAG
CAACTCCAACAATATGCAGAGTCTCGCGAACTTGACCATCTTGGACTTGATGATCAGGAAAAGAAAATTC
TTATGAACTTCCATCAGAAAAAGAACGAAATCAGCTTCCAGCAAACAAACGCTATGGTAACTCTAAGAAA
AGAGCGCCTGGCCAAGCTGACAGAAGCTATCACTGCTGCGTCACTGCCCAAAACAAGTGGACATTACGAT
GATGATGACGACATTCCCTTTCCAGGACCCATCAATGATGACGACAATCCTGGCCATCAAGATGATGATCC
GACTGACTCACAGGATACGACCATTCCCGATGTGGTGGTTGATCCCGATGATGGAAGCTACGGCGAATAC
CAGAGTTACTCGGAAAACGGCATGAATGCACCAGATGACTTGGTCCTATTCGATCTAGACGAGGACGACG
AGGACACTAAGCCAGTGCCTAATAGATCGACCAAGGGTGGACAACAGAAGAACAGTCAAAAGGGCCAGC
ATATAGAGGGCAGACAGACACAATCCAGGCCAATTCAAAATGTCCCAGGCCCTCACAGAACAATCCACCA
CGCCAGTGCGCCACTCACGGACAATGACAGAAGAAATGAACCCTCCGGCTCAACCAGCCCTCGCATGCTG
ACACCAATTAACGAAGAGGCAGACCCACTGGACGATGCCGACGACGAGACGTCTAGCCTTCCGCCCTTGG
AGTCAGATGATGAAGAGCAGGACAGGGACGGAACTTCCAACCGCACACCCACTGTCGCCCCACCGGCTCC
CGTATACAGAGATCACTCTGAAAAGAAAGAACTCCCGCAAGACGAGCAACAAGATCAGGACCACACTCA
AGAGGCCAGGAACCAGGACAGTGACAACACCCAGTCAGAACACTCTTTTGAGGAGATGTATCGCCACATT
CTAAGATCACAGGGGCCATTTGATGCTGTTTTGTATTATCATATGATGAAGGATGAGCCTGTAGTTTTCAG
TACCAGTGATGGCAAAGAGTACACGTATCCAGACTCCCTTGAAGAGGAATATCCACCATGGCTCACTGAA
AAAGAGGCTATGAATGAAGAGAATAGATTTGTTACATTGGATGGTCAACAATTTTATTGGCCGGTGATGA
ATCACAAGAATAAATTCATGGCAATCCTGCAACATCATCAGTGA
GP:ATGtacgatgttccagattacgctgctgctGGCGTTACAGGAATATTGCAGTTACCTCGTGATCGATTCAAGAGGACAT
CATTCTTTCTTTGGGTAATTATCCTTTTCCAAAGAACATTTTCCATCCCACTTGGAGTCATCCACAATAGCA
CATTACAGGTTAGTGATGTCGACAAACTAGTTTGTCGTGACAAACTGTCATCCACAAATCAATTGAGATCA
GTTGGACTGAATCTCGAAGGGAATGGAGTGGCAACTGACGTGCCATCTGCAACTAAAAGATGGGGCTTCA
GGTCCGGTGTCCCACCAAAGGTGGTCAATTATGAAGCTGGTGAATGGGCTGAAAACTGCTACAATCTTGA
AATCAAAAAACCTGACGGGAGTGAGTGTCTACCAGCAGCGCCAGACGGGATTCGGGGCTTCCCCCGGTGC
CGGTATGTGCACAAAGTATCAGGAACGGGACCGTGTGCCGGAGACTTTGCCTTCCATAAAGAGGGTGCTT
TCTTCCTGTATGATCGACTTGCTTCCACAGTTATCTACCGAGGAACGACTTTCGCTGAAGGTGTCGTTGCAT
TTCTGATACTGCCCCAAGCTAAGAAGGACTTCTTCAGCTCACACCCCTTGAGAGAGCCGGTCAATGCAACG
GAGGACCCGTCTAGTGGCTACTATTCTACCACAATTAGATATCAGGCTACCGGTTTTGGAACCAATGAGAC
AGAGTACTTGTTCGAGGTTGACAATTTGACCTACGTCCAACTTGAATCAAGATTCACACCACAGTTTCTGC
TCCAGCTGAATGAGACAATATATACAAGTGGGAAAAGGAGCAATACCACGGGAAAACTAATTTGGAAGG
TCAACCCCGAAATTGATACAACAATCGGGGAGTGGGCCTTCTGGGAAACTAAAAAAAACCTCACTAGAAA
AATTCGCAGTGAAGAGTTGTCTTTCACAGTTGTATCAAACGGAGCCAAAAACATCAGTGGTCAGAGTCCG
GCGCGAACTTCTTCCGACCCAGGGACCAACACAACAACTGAAGACCACAAAATCATGGCTTCAGAAAATT
CCTCTGCAATGGTTCAAGTGCACAGTCAAGGAAGGGAAGCTGCAGTGTCGCATCTAACAACCCTTGCCAC
AATCTCCACGAGTCCCCAATCCCTCACAACCAAACCAGGTCCGGACAACAGCACCCATAATACACCCGTG
TATAAACTTGACATCTCTGAGGCAACTCAAGTTGAACAACATCACCGCAGAACAGACAACGACAGCACAG
CCTCCGACACTCCCTCTGCCACGACCGCAGCCGGACCCCCAAAAGCAGAGAACACCAACACGAGCAAGA
GCACTGACTTCCTGGACCCCGCCACCACAACAAGTCCCCAAAACCACAGCGAGACCGCTGGCAACAACAA
CACTCATCACCAAGATACCGGAGAAGAGAGTGCCAGCAGCGGGAAGCTAGGCTTAATTACCAATACTATT
GCTGGAGTCGCAGGACTGATCACAGGCGGGAGAAGAACTCGAAGAGAAGCAATTGTCAATGCTCAACCC
AAATGCAACCCTAATTTACATTACTGGACTACTCAGGATGAAGGTGCTGCAATCGGACTGGCCTGGATAC
CATATTTCGGGCCAGCAGCCGAGGGAATTTACATAGAGGGGCTAATGCACAATCAAGATGGTTTAATCTG
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TGGGTTGAGACAGCTGGCCAACGAGACGACTCAAGCTCTTCAACTGTTCCTGAGAGCCACAACTGAGCTA
CGCACCTTTTCAATCCTCAACCGTAAGGCAATTGATTTCTTGCTGCAGCGATGGGGCGGCACATGCCACAT
TCTGGGACCGGACTGCTGTATCGAACCACATGATTGGACCAAGAACATAACAGACAAAATTGATCAGATT
ATTCATGATTTTGTTGATAAAACCCTTCCGGACCAGGGGGACAATGACAATTGGTGGACAGGATGGAGAC
AATGGATACCGGCAGGTATTGGAGTTACAGGCGTTATAATTGCAGTTATCGCTTTATTCTGTATATGCAAA
TTTGTCTTTTAG
L:
ATGGCTACACAACATACCCAATACCCAGACGCTAGGTTATCATCACCAATTGTATTGGACCAATGTGACCT
AGTCACTAGAGCTTGCGGGTTATATTCATCATACTCCCTTAATCCGCAACTACGCAACTGTAAACTCCCGA
AACATATCTACCGTTTGAAATACGATGTAACTGTTACCAAGTTCTTGAGTGATGTACCAGTGGCGACATTG
CCCATAGATTTCATAGTCCCAGTTCTTCTCAAGGCACTGTCAGGCAATGGATTCTGTCCTGTTGAGCCGCG
GTGCCAACAGTTCTTAGATGAAATCATTAAGTACACAATGCAAGATGCTCTCTTCTTGAAATATTATCTCA
AAAATGTGGGTGCTCAAGAAGACTGTGTTGATGAACACTTTCAAGAGAAAATCTTATCTTCAATTCAGGG
CAATGAATTTTTACATCAAATGTTTTTCTGGTATGATCTGGCTATTTTAACTCGAAGGGGTAGATTAAATCG
AGGAAACTCTAGATCAACATGGTTTGTTCATGATGATTTAATAGACATCTTAGGCTATGGGGACTATGTTT
TTTGGAAGATCCCAATTTCAATGTTACCACTGAACACACAAGGAATCCCCCATGCTGCTATGGACTGGTAT
CAGGCATCAGTATTCAAAGAAGCGGTTCAAGGGCATACACACATTGTTTCTGTTTCTACTGCCGACGTCTT
GATAATGTGCAAAGATTTAATTACATGTCGATTCAACACAACTCTAATCTCAAAAATAGCAGAGATTGAG
GATCCAGTTTGTTCTGATTATCCCAATTTTAAGATTGTGTCTATGCTTTACCAGAGCGGAGATTACTTACTC
TCCATATTAGGGTCTGATGGGTATAAAATTATTAAGTTCCTCGAACCATTGTGCTTGGCCAAAATTCAATT
ATGCTCAAAGTACACTGAGAGGAAGGGCCGATTCTTAACACAAATGCATTTAGCTGTAAATCACACCCTA
GAAGAAATTACAGAAATGCGTGCACTAAAGCCTTCACAGGCTCAAAAGATCCGTGAATTCCATAGAACAT
TGATAAGGCTGGAGATGACGCCACAACAACTTTGTGAGCTATTTTCCATTCAAAAACACTGGGGGCATCCT
GTGCTACATAGTGAAACAGCAATCCAAAAAGTTAAAAAACATGCTACGGTGCTAAAAGCATTACGCCCTA
TAGTGATTTTCGAGACATACTGTGTTTTTAAATATAGTATTGCCAAACATTATTTTGATAGTCAAGGATCTT
GGTACAGTGTTACTTCAGATAGGAATCTAACACCGGGTCTTAATTCTTATATCAAAAGAAATCAATTCCCT
CCGTTGCCAATGATTAAAGAACTACTATGGGAATTTTACCACCTTGACCACCCTCCACTTTTCTCAACCAA
AATTATTAGTGACTTAAGTATTTTTATAAAAGACAGAGCTACCGCAGTAGAAAGGACATGCTGGGATGCA
GTATTCGAGCCTAATGTTCTAGGATATAATCCACCTCACAAATTTAGTACTAAACGTGTACCGGAACAATT
TTTAGAGCAAGAAAACTTTTCTATTGAGAATGTTCTTTCCTACGCACAAAAACTCGAGTATCTACTACCAC
AATATCGGAACTTTTCTTTCTCATTGAAAGAGAAAGAGTTGAATGTAGGTAGAACCTTCGGAAAATTGCCT
TATCCGACTCGCAATGTTCAAACACTTTGTGAAGCTCTGTTAGCTGATGGTCTTGCTAAAGCATTTCCTAGC
AATATGATGGTAGTTACGGAACGTGAGCAAAAAGAAAGCTTATTGCATCAAGCATCATGGCACCACACAA
GTGATGATTTTGGTGAACATGCCACAGTTAGAGGGAGTAGCTTTGTAACTGATTTAGAGAAATACAATCTT
GCATTTAGATATGAGTTTACAGCACCTTTTATAGAATATTGCAACCGTTGCTATGGTGTTAAGAATGTTTTT
AATTGGATGCATTATACAATCCCACAGTGTTATATGCATGTCAGTGATTATTATAATCCACCACATAACCT
CACACTGGAGAATCGAGACAACCCCCCCGAAGGGCCTAGTTCATACAGGGGTCATATGGGAGGGATTGAA
GGACTGCAACAAAAACTCTGGACAAGTATTTCATGTGCTCAAATTTCTTTAGTTGAAATTAAGACTGGTTT
TAAGTTACGCTCAGCTGTGATGGGTGACAATCAGTGCATTACTGTTTTATCAGTCTTCCCCTTAGAGACTG
ACGCAGACGAGCAGGAACAGAGCGCCGAAGACAATGCAGCGAGGGTGGCCGCCAGCCTAGCAAAAGTTA
CAAGTGCCTGTGGAATCTTTTTAAAACCTGATGAAACATTTGTACATTCAGGTTTTATCTATTTTGGAAAA
AAACAATATTTGAATGGGGTCCAATTGCCTCAGTCCCTTAAAACGGCTACAAGAATGGCACCATTGTCTGA
TGCAATTTTTGATGATCTTCAAGGGACCCTGGCTAGTATAGGCACTGCTTTTGAGCGATCCATCTCTGAGA
CACGACATATCTTTCCTTGCAGGATAACCGCAGCTTTCCATACGTTTTTTTCGGTGAGAATCTTGCAATATC
ATCATCTCGGGTTCAATAAAGGTTTTGACCTTGGACAGTTAACACTCGGCAAACCTCTGGATTTCGGAACA
ATATCATTGGCACTAGCGGTACCGCAGGTGCTTGGAGGGTTATCCTTCTTGAATCCTGAGAAATGTTTCTA
CCGGAATCTAGGAGATCCAGTTACCTCAGGCTTATTCCAGTTAAAAACTTATCTCCGAATGATTGAGATGG
ATGATTTATTCTTACCTTTAATTGCGAAGAACCCTGGGAACTGCACTGCCATTGACTTTGTGCTAAATCCTA
GCGGATTAAATGTCCCTGGGTCGCAAGACTTAACTTCATTTCTGCGCCAGATTGTACGCAGGACCATCACC
CTAAGTGCGAAAAACAAACTTATTAATACCTTATTTCATGCGTCAGCTGACTTCGAAGACGAAATGGTTTG
TAAATGGCTATTATCATCAACTCCTGTTATGAGTCGTTTTGCGGCCGATATCTTTTCACGCACGCCGAGCG
GGAAGCGATTGCAAATTCTAGGATACCTGGAAGGAACACGCACATTATTAGCCTCTAAGATCATCAACAA
TAATACAGAGACACCGGTTTTGGACAGACTGAGGAAAATAACATTGCAAAGGTGGAGCCTATGGTTTAGT
TATCTTGATCATTGTGATAATATCCTGGCGGAGGCTTTAACCCAAATAACTTGCACAGTTGATTTAGCACA
GATTCTGAGGGAATATTCATGGGCTCATATTTTAGAGGGAAGACCTCTTATTGGAGCCACACTCCCATGTA
TGATTGAGCAATTCAAAGTGTTTTGGCTGAAACCCTACGAACAATGTCCGCAGTGTTCAAATGCAAAGCA
ACCAGGTGGGAAACCATTCGTGTCAGTGGCAGTCAAGAAACATATTGTTAGTGCATGGCCGAACGCATCC
CGAATAAGCTGGACTATCGGGGATGGAATCCCATACATTGGATCAAGGACAGAAGATAAGATAGGACAA
CCTGCTATTAAACCAAAATGTCCTTCCGCAGCCTTAAGAGAGGCCATTGAATTGGCGTCCCGTTTAACATG
GGTAACTCAAGGCAGTTCGAACAGTGACTTGCTAATAAAACCATTTTTGGAAGCACGAGTAAATTTAAGT
GTTCAAGAAATACTTCAAATGACCCCTTCACATTACTCAGGAAATATTGTTCACAGGTACAACGATCAATA
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CAGTCCTCATTCTTTCATGGCCAATCGTATGAGTAATTCAGCAACGCGATTGATTGTTTCTACAAACACTTT
AGGTGAGTTTTCAGGAGGTGGCCAGTCTGCACGCGACAGCAATATTATTTTCCAGAATGTTATAAATTATG
CAGTTGCACTGTTCGATATTAAATTTAGAAACACTGAGGCTACAGATATCCAATATAATCGTGCTCACCTT
CATCTAACTAAGTGTTGCACCCGGGAAGTACCAGCTCAGTATTTAACATACACATCTACATTGGATTTAGA
TTTAACAAGATACCGAGAAAACGAATTGATTTATGACAGTAATCCTCTAAAAGGAGGACTCAATTGCAAT
ATCTCATTCGATAATCCATTTTTCCAAGGTAAACGGCTGAACATTATAGAAGATGATCTTATTCGACTGCC
TCACTTATCTGGATGGGAGCTAGCCAAGACCATCATGCAATCAATTATTTCAGATAGCAACAATTCATCTA
CAGACCCAATTAGCAGTGGAGAAACAAGATCATTCACTACCCATTTCTTAACTTATCCCAAGATAGGACTT
CTGTACAGTTTTGGGGCCTTTGTAAGTTATTATCTTGGCAATACAATTCTTCGGACTAAGAAATTAACACTT
GACAATTTTTTATATTACTTAACTACTCAAATTCATAATCTACCACATCGCTCATTGCGAATACTTAAGCCA
ACATTCAAACATGCAAGCGTTATGTCACGGTTAATGAGTATTGATCCTCATTTTTCTATTTACATAGGCGGT
GCTGCAGGTGACAGAGGACTCTCAGATGCGGCCAGGTTATTTTTGAGAACGTCCATTTCATCTTTTCTTAC
ATTTGTAAAAGAATGGATAATTAATCGCGGAACAATTGTCCCTTTATGGATAGTATATCCGCTAGAGGGTC
AAAACCCAACACCTGTGAATAATTTTCTCTATCAGATCGTAGAACTGCTGGTGCATGATTCATCAAGACAA
CAGGCTTTTAAAACTACCATAAGTGATCATGTACATCCTCACGACAATCTTGTTTACACATGTAAGAGTAC
AGCCAGCAATTTCTTCCATGCATCATTGGCGTACTGGAGGAGCAGACACAGAAACAGCAACCGAAAATAC
TTGGCAAGAGACTCTTCAACTGGATCAAGCACAAACAACAGTGATGGTCATATTGAGAGAAGTCAAGAAC
AAACCACCAGAGATCCACATGATGGCACTGAACGGAATCTAGTCCTACAAATGAGCCATGAAATAAAAA
GAACGACAATTCCACAAGAAAACACGCACCAGGGTCCGTCGTTCCAGTCCTTTCTAAGTGACTCTGCTTGT
GGTACAGCAAATCCAAAACTAAATTTCGATCGATCGAGACACAATGTGAAATTTCAGGATCATAACTCGG
CATCCAAGAGGGAAGGTCATCAAATAATCTCACACCGTCTAGTCCTACCTTTCTTTACATTATCTCAAGGG
ACACGCCAATTAACGTCATCCAATGAGTCACAAACCCAAGACGAGATATCAAAGTACTTACGGCAATTGA
GATCCGTCATTGATACCACAGTTTATTGTAGATTTACCGGTATAGTCTCGTCCATGCATTACAAACTTGATG
AGGTCCTTTGGGAAATAGAGAGTTTCAAGTCGGCTGTGACGCTAGCAGAGGGAGAAGGTGCTGGTGCCTT
ACTATTGATTCAGAAATACCAAGTTAAGACCTTATTTTTCAACACGCTAGCTACTGAGTCCAGTATAGAGT
CAGAAATAGTATCAGGAATGACTACTCCTAGGATGCTTCTACCTGTTATGTCAAAATTCCATAATGACCAA
ATTGAGATTATTCTTAACAACTCAGCAAGCCAAATAACAGACATAACAAATCCTACTTGGTTTAAAGACC
AAAGAGCAAGGCTACCTAAGCAAGTCGAGGTTATAACCATGGATGCAGAGACAACAGAGAATATAAACA
GATCGAAATTGTACGAAGCTGTATATAAATTGATCTTACACCATATTGATCCTAGCGTATTGAAAGCAGTG
GTCCTTAAAGTCTTTCTAAGTGATACTGAGGGTATGTTATGGCTAAATGATAATTTAGCCCCGTTTTTTGCC
ACTGGTTATTTAATTAAGCCAATAACGTCAAGTGCTAGATCTAGTGAGTGGTATCTTTGTCTGACGAACTT
CTTATCAACTACACGTAAGATGCCACACCAAAACCATCTCAGTTGTAAACAGGTAATACTTACGGCATTGC
AACTGCAAATTCAACGAAGCCCATACTGGCTAAGTCATTTAACTCAGTATGCTGACTGTGAGTTACATTTA
AGTTATATCCGCCTTGGTTTTCCATCATTAGAGAAAGTACTATACCACAGGTATAACCTCGTCGATTCAAA
AAGAGGTCCACTAGTCTCTATCACTCAGCACTTAGCACATCTTAGAGCAGAGATTCGAGAATTAACTAATG
ATTATAATCAACAGCGACAAAGTCGGACTCAAACATATCACTTTATTCGTACTGCAAAAGGACGAATCAC
AAAACTAGTCAATGATTATTTAAAATTCTTTCTTATTGTGCAAGCATTAAAACATAATGGGACATGGCAAG
CTGAGTTTAAGAAATTACCAGAGTTGATTAGTGTGTGCAATAGGTTCTACCATATTAGAGATTGCAATTGT
GAAGAACGTTTCTTAGTTCAAACCTTATATTTACATAGAATGCAGGATTCTGAAGTTAAGCTTATCGAAAG
GCTGACAGGGCTTCTGAGTTTATTTCCGGATGGTCTCTACAGGTTTGATTGA

* CG dinucleotides are underlined
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Appendix B. Knockdown efficiencies for shRNAs and siRNAs used within this study.
293T cells were transfected with either an shRNA targeting a scrambled sequence of RNA
(ScrambledshRNA in A and C) or an siRNA targeting a scrambled sequence (ScrambledsiRNA
in B) as a control. To measure knockdown efficiency, cells were transfected with either
(A) HERC5shRNA (shHERC5), (B) HERC5siRNA (siHERC5) or (C) ZAPshRNA (shZAP) and
RNA levels were measured using qPCR. Knockdown efficiencies were 44%, 60% and 58%
respectively. **P<0.01, *P<0.05. Student’s paired T test.
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Appendix C. Copyright permissions for figures 1-2.
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